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1. Abstract 
Symmetrical gene dosage imbalances at 7q11.23 chromosomal region cause two 
unique neurodevelopmental diseases, Williams Beuren Syndrome (WBS) and the 7q11.23 
microduplication associated to autistic spectrum disorder (7dup-ASD).  Although both these 
diseases share common features such as intellectual disability and craniofacial dysmorphism, 
they can be distinguished by distinct social and language abilities: WBS patients characterized 
by hypersociality and comparatively well-preserved language skills while 7dup-ASD is 
associated with impairment in social interaction and communicative skills. The involvement 
of same genetic interval in these disease, points out to small subset of dosage-sensitive genes 
affecting cognition, social behavior and communication skills.  
Among the genes in the deleted region, some were shown to contribute to the 
abnormalities in these patients through transgenic mice models and individual case reports. 
However, the precise cellular and molecular phenotypes associated with these syndromes in 
disease-relevant cell-types are unknown due to the scarce availability of primary diseased 
tissues. Transcription factor induced somatic cell reprogramming has bypassed such 
fundamental limitation and has enabled us to model human diseases, elucidate their 
pathogenesis and discover new therapeutics by screening small chemicals/drugs on these 
models. During my PhD studies, I focused on the functional dissection of these 
complementary diseases at the level of transcriptional deregulation in patient-derived iPSC 
and its differentiated derivatives such as neural crest stem cells, mesenchymal stem cells, and 
neural progenitors. To this end, we have assembled a unique cohort of typical WBS, atypical 
WBS (patient with a partial deletion) and 7dup-ASD patients (along with unaffected relatives), 
and then I used mRNA reprogramming to establish and characterize at least 3 independent 
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iPSC lines from a total of 12 individuals. High throughput mRNA sequencing on iPSC 
revealed critical transcriptional derangements in disease-relevant pathways already at the 
pluripotent state. These alterations found to be selectively amplified upon differentiation into 
disease-relevant lineages, thereby establishing the value of large iPSC cohorts in the 
elucidation of disease-relevant developmental pathways. Finally, we created an open-access 
web-based platform to make accessible our multi-layered datasets and integrate contributions 
by the entire community working on the molecular dissection of the 7q11.23 syndromes. 
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2. Introduction 
 
The q11.23 genetic interval on human chromosome 7 contains genes that play crucial 
role in two human genetic neurodevelopmental diseases: Williams Beuren Syndrome (WBS; 
OMIM 194050) and Williams-Beuren region duplication syndrome (also known as 
Somerville-van der Aa syndrome, OMIM 609757) (Pober 2010, Sanders, Ercan-Sencicek et 
al. 2011). The hemizygous deletion of this region containing 26-28 genes (1.5-1.8 Mbp) 
causes WBS, a condition characterized by  craniofacial dysmorphic features, cardiovascular 
defects and intellectual disability; further distinguished by hypersociality and comparatively 
well-preserved language skills (Pober 2010). On the contrary, the duplication of the same 
interval that has been recently reported in a subset of ASD patients (7dup-ASD) is associated 
with impairment in social interaction and communicative skills (Sanders, Ercan-Sencicek et al. 
2011). This points out to the importance of small subset of dosage-sensitive genes within this 
interval affecting cognition, social behavior and communication skills. 
2.1. Mechanisms of rearrangements at 7q11.23 
 
The 7 q11.23 microdeletion/duplication occurs due to the unique genetic architecture 
of this interval. Williams–Beuren syndrome chromosome region (WBSCR) is flanked by 
highly homologous clusters of genes/pseudogenes (also known as low-copy-repeat blocks or 
duplicons) (Pober 2010). The high degree of sequence homology among these flanking 
duplicons, as well as their proximity to each other, makes WBSCR highly susceptible to non-
allelic homologous recombination (NAHR) that in turn mediates duplications and deletions 
during meiosis. Patients with deletion of WBSCR carry one copy of all genes within this 
18 
 
 
interval while patients with duplication carry three copies of this interval (Merla, Brunetti-
Pierri et al. 2010, Pober 2010). The lists of the WBSCR genes and the mechanism of the 
rearrangement are depicted in Fig. 1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.1.1.  
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Fig. 1.1 The Williams–Beuren syndrome chromosome region (WBSCR) on chromosome 7.  
Panel A shows the list of WBS genes and that the WBSCR located between flanking 
duplicons.  Panel B shows normal pairing of the two copies of the WBSCR during meiosis 
caused by alignment of the duplicons on the chromosome 7 homologues. Panel C shows 
abnormal pairing of the two copies of the WBSCR during meiosis, caused by misalignment of 
the duplicons due to their partial homology. Crossing over can result in abnormal recombinant 
products, either deletion of the WBSCR (causing Williams–Beuren syndrome) or duplication 
of WBSCR (causing 7dup-ASD) (Adapted from (Pober 2010)). 
2.2. Diagnosis  
Historically WBS was diagnosed by FISH on metaphase chromosomes using a probe 
for the Elastin gene (Ewart, Morris et al. 1993, Merla, Brunetti-Pierri et al. 2010). In spite of 
being labor-intensive, time-consuming, and not highly accurate, FISH is yet the most wildly 
used method for clinical diagnosis of WBS. However, FISH interpretation for duplications 
makes interphase FISH highly problematic for the diagnosis of 7q11.23 duplication syndrome. 
For all these reasons, various techniques have been recently developed and exploited to 
improve the detection methods including qPCR, multiplex ligation dependent probe 
amplification (MLPA) and aCGH (Shaffer, Kennedy et al. 1997, Sellner and Taylor 2004, 
Schubert and Laccone 2006, Merla, Brunetti-Pierri et al. 2010, Sanders, Ercan-Sencicek et al. 
2011).  
In brief, qPCR is a precise method which allows estimation of the relative quantity of 
the analyzed locus assays within and outside the segmental aneuploidy (Schubert and Laccone 
2006). Another efficient and reliable method is MLPA which can assess the dosage of the 
multiple genomic loci based on the synthetic probe (Sellner and Taylor 2004); and finally 
aCGH is a microarray based technology which can detect the copy number variations in 
highly sensitive way (Sanders, Ercan-Sencicek et al. 2011). Interestingly, thanks to these 
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methods, it has been found that there is a high frequency of parental transmission in 7q11.23 
duplication patients which is in contrast with the rarity of parental transmission in the WBS 
(Merla, Brunetti-Pierri et al. 2010).  
 
2.3.Williams Beuren syndrome 
Williams Beuren syndrome (also known as William’s syndrome) is a developmental 
disorder with a prevalence of roughly 1-10,000 person (Pober 2010).  Although teratogenicity 
of vitamin D initially considered as the cause of disease based on the experiments that linked 
vitamin D with some symptoms of William’s syndrome such as craniofacial and 
cardiovascular abnormalities, later studies showed that it’s an autosomal dominant genetic 
disorder (Friedman and Roberts 1966, Morris, Thomas et al. 1993, Sadler, Robinson et al. 
1993).  
 Fig.1.2 Patients with Williams–Beuren Syndrome.  
Four unrelated patients with Williams–Beuren syndrome are shown in Panels A through D. 
The young child (Panel A) has a flat nose bridge, upturned tip of nose, long philtrum, mild 
periorbital puffiness, full cheeks, and a delicate chin. The school-age child (Panel B) has full 
lips, a wide mouth, and mildly increased interdental spacing. The young adult (Panel C) has a 
prominent nose and nasal tip, a wide mouth, and a full lower lip. Panel D shows a patient at 12 
years of age (left) and at 83 years of age (right) (Adapted from (Pober 2010)). 
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As mentioned above, the hallmarks of the disease are low to mild intellectual 
disability, subtle to dramatic craniofacial features (Fig.1.2 ) and cardiovascular abnormalities 
which are listed and discussed below along with the possible role of individual genes in each 
phenotype: 
2.3.1. Neurodevelopmental abnormalities 
WBS patients have impaired (mild-to-moderate) intellectual disability with full-scale 
IQ averaging 50 to 60. They also exhibit dramatic weaknesses in visuospatial skills that is 
ability to visualize an object as a set of parts and construct a replica of the object from those 
parts. Fig. 1.3 compares the spatial deficits in William’s syndrome with age and IQ match 
individual affected by Down syndrome (Bellugi, Lichtenberger et al. 1999, Meyer-
Lindenberg, Mervis et al. 2006). 
 
 
 
 
 
 
 
Fig. 1.3 Different spatial deficits in William’s syndrome (WBS) and Down syndrome (DNS).   
A) The drawings by adolescents and adults with WBS contain many parts of houses but they 
are not organized coherently. In contrast, the drawings of age-matched and Full Scale IQ-
matched DNS adults are simplified but have the correct overall gestalt. B) In the block-design 
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task both subjects with WBS and subjects with DNS fail, but they fail in very different ways. 
C) In the Delis hierarchical processing task, subjects are asked to copy a large global figure 
made of smaller local forms (a ‘D’ made out of ‘Y’s). Again, both groups fail but in 
significantly different ways: subjects with WBS tend to produce the local elements sprinkled 
across the page, whereas age-matched and Full Scale IQ-matched subjects with DNS tend to 
produce only the global forms. (Adapted from (Bellugi, Lichtenberger et al. 1999)). 
 
WBS patients also exhibit relative strengths in auditory rote memory, selected aspects 
of language, recognition and discrimination and social and interpersonal skills. Another well 
described feature of WBS patients is hypersociability which is combined with anxiety 
disorder, phobic disorder, attention deficit–hyperactivity disorder in 50-90 percent of the WBS 
adults which over all, have a major impact on the quality of life of most people with Williams 
Beuren syndrome (Merla, Brunetti-Pierri et al. 2010, Pober 2010). 
Neurologic examination and brain imaging using standard magnetic resonance imaging 
(MRI) reveals an overall 10 to 15% reduction in cerebral volume, with preserved cerebellar 
volume. Functional MRI studies also suggest that impaired limbic circuitry may underlie the 
unique anxiety profile of Williams–Beuren syndrome (Fig. 1.4) (Meyer-Lindenberg, Mervis et 
al. 2006, Jarvinen-Pasley, Bellugi et al. 2008). 
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Fig. 1.4 Summary of neurobiological findings in WBS.  
(Adapted from (Jarvinen-Pasley, Bellugi et al. 2008)). 
 
Several genes have been implicated to be involved in the cognitive and behavioral 
phenotypes of WBS through mouse model studies: 
CAP-Gly domain-containing linker protein 2 (CLIP2) belongs to a family of 
cytoplasmic linker proteins and regulate the cytoskeleton through the microtubule network. 
CLIP2 is abundantly expressed in neurons of the hippocampus, piriform cortex, and olfactory 
bulb. The mice model of this gene exhibit hippocampal dysfunction revealed by deficits in 
contextual fear conditioning and altered synaptic plasticity, however, no changes in the size or 
structure of the brain were observed.  Both in hetrozygotes and homozygotes models impaired 
motor coordination on some tasks were observed but no changes in amygdale function or 
anxiety were seen (Hoogenraad, Koekkoek et al. 2002).  
LIM kinase 1 (LIMK1) is a serine protein kinase involved in regulation of cytoskeletal 
integrity and remodeling through organization of the actin dynamics (Proschel, Blouin et al. 
1995). LIMK1 is expressed in the central nervous system and in particular accumulates at the 
level of mature synapses, suggesting that it could play a role in synapse formation and/or 
maintenance (Scott and Olson 2007).  In addition, the role of the actin remodeling in the 
establishment and modification of dendritic spines especially in the hippocampus suggest its 
putative role in the formation and maintenance of memory and learning (Nimchinsky, Sabatini 
et al. 2002). Likewise CLIP2, LIMK1 mice model shares some common phenotype with 
CTIP2 such as hippocampal dysfunction and no altered abnormality in brain size and 
structure. However, Limk1-null mice in contrast exhibited altered dendritic spine morphology 
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in pyramidal neurons which is also observed in many syndromes such as Down and fragile X 
syndromes which all share intellectual disability as a common phenotype. No analysis of the 
Limk1 heterozygotes was reported in the same study (Kaufmann and Moser 2000).  
General transcription factor 2-I (GTF2I), GTF2I repeat domain containing protein 1 
and 1 (GTF2IRD1) , and GTF2I repeat domain containing protein 2 (GTF2IRD2) all belong to 
the TFII-I gene family encoding transcription factors with multiple helix-loop-helix (HLH)-
like domains, also known as I-repeats (Hinsley, Cunliffe et al. 2004). Genomic alignments 
suggest that GTF2IRD2 is a truncated version of GTF2I. GTF2IRD2 is deleted only in WBS 
patients with the rarer 1.84-Mb deletions, while GTF2IRD1 and GTF2I are deleted in all cases 
with typical deletions (Bayes, Magano et al. 2003). 
Studies on the heterozygous and homozygous mice for Gtf2ird1indeed showed that 
both of these mice have some phenotypes which correlate with increased sociability and lack 
of social anxiety in WBS patients. For instance these mice showed increased social 
interaction, reduced anxiety and impaired amygdala-based learning and memory. However, 
unlike, CLIP2 and LIMK1 mice, hippocampal function showed to be intact. Enhanced 
serotonin receptor1A-mediated responses in layer V pyramidal neurons of the pre-frontal 
cortex were also reported in Gtf2ird1mice model (Palmer, Tay et al. 2007, Young, Lipina et 
al. 2008). 
GTF2I is ubiquitously expressed and it can interact with multiple proteins and DNA, 
linking signal transduction to transcription. GTF2I also acts as a multifunctional transcription 
factor that can bind enhancer (E-box) and core promoter (Inr) elements in response to 
upstream signaling events (Roy, Du et al. 1997). The GTF2I genes have been also nominated 
initially as the candidate genes involved in cognitive and behavioral profile of WBS patients 
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through the study of patient with atypical deletion. Enkhmandakh et al. generated a Gtf2i 
gene-trap mouse model using a gene-trap cassette technology in which the cassette was 
inserted into intron 3 of Gtf2i. They reported that this mouse does not survive later than E10.5, 
and embryonic hemorrhage and cardiovascular malformations were discerned at E9.5. While 
about 60% of the homozygote embryos had neural tube defects, growth delay was apparent in 
the heterozygote mice (Enkhmandakh, Makeyev et al. 2009). 
In another attempt Sakurai et al. (2010) generated a mouse model using a similar 
approach. Similar to the previous study this mouse did not produce any homozygouse animals 
and Gtf2i-null embryos were exencephalic however, they did not exhibit developmental and 
cardiovascular abnormalities which are in contrast with former study.  In terms of behavioral 
assays, Gtf2i+/- animals did not exhibit any alterations in spatial and non-spatial learning and 
memory, anxiety and neuromotor function (Sakurai, Dorr et al. 2011). 
2.3.2. Cardiovascular abnormalities 
In general cardiovascular defects are the major cause of death in WBS patients. They 
occur 25-100 times more with respect to the healthy individuals. Supravalvular aortic stenosis 
(SVAS) is the most common cardiovascular abnormality of Williams–Beuren syndrome 
affecting approximately 70 percent of the patients (Pober 2010).  
Previous studies have found a strong link between Elastin (ELN) and SVAS and other 
connective tissue abnormalities of WBS patients (Ewart, Morris et al. 1993). Various studies 
also showed that SVAS is due to the over growth of the smooth muscle cells within vascular 
media (Pober 2010).  Elastin is mainly responsible for the formation of the elastic fibers of the 
extracellular matrix throughout connective tissue of the body.  Reduction of vascular 
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elasticity, due to elastin haploinsufciency, may increase the hemodynamic stress to the 
endothelium, which in turn leads to over growth of smooth muscle and subsequently 
narrowing of the vessels (Karnik, Brooke et al. 2003). However, the pathogenesis of the 
arteriopathy in WBS may be more complex, and is possibly related to other genes in the WBS 
critical region such as NCF1 (Del Campo, Antonell et al. 2006, Merla, Brunetti-Pierri et al. 
2010).  
Homozygous knock-out mice for elastin is not viable and die right after birth due to 
aortic obstruction caused by smooth muscle cell proliferation in the arterial wall. However, 
heterozygous mice are viable and produce half of the Eln mRNA and protein. They also 
exhibit hypertension, thinner elastic lamellae, decreased aortic compliance, and mild cardiac 
hypertrophy (Li, Brooke et al. 1998, Li, Faury et al. 1998). Importantly, the Eln mouse model 
does not show SVAS but interestingly, Eln heterozygosity in a transgenic mouse carrying a 
human version of ELN on a bacterial artificial chromosome resulted in thickening of the wall 
of the ascending aorta which suggests a fundamental difference in the function of the mouse 
and human ELN gene in the developing aorta (Hirano, Knutsen et al. 2007) . 
Another gene which has been shown to have a role in the development of heart is 
BAZ1B (encoding WSTF) that has roles in DNA repair, replication, transcriptional activation 
and repression, and also possesses histone H2A kinase activity (Barnett and Krebs 2011). 
WSTF is a shared subunit of three distinct chromatin remodeling complexes; WICH (WSTF-
ISWI chromatin remodeling complex) for DNA repair and WINAC (WSTF including the 
nucleosome assembly complex) for transcriptional control and B-WICH (Barnett and Krebs 
2011, Barnett, Yazgan et al. 2012). BAZ1B knockout mice exhibit major heart defects and 
dies shortly after birth, however, heterozygous mice shows range of developmental heart 
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abnormalities similar to those have been reported in WBS. Moreover, expression of some key 
transcriptional regulators involved in heart development such as Gja5 and Irx3 shown to be 
altered in these mice (Yoshimura, Kitagawa et al. 2009).  
2.3.3. Craniofacial dysmorphisim 
Craniofacial abnormalities considered as one of the distinctive features of these patient 
and they include (but are not limited to) broad forehead, periorbital fullness, epicanthal folds, 
flat nasal bridge, a short upturned nose, long philtrum, and wide mouth with full lips, full 
cheeks, small jaw excessive  and interdental spacing (Pober 2010).  
The two important genes proposed so far to be involved in craniofacial feature of WBS 
patient based on the existing mouse models are Gtf2ird1 and Baz1b.  Briefly Gtf2ird1 
homozygous knock out mouse exhibit periorbital fullness and a short snout misaligned jaws 
and a twisted snout. However, the heterozygous mice, showed normal craniofacial 
development (Tassabehji, Hammond et al. 2005, Palmer, Tay et al. 2007, Young, Lipina et al. 
2008) .  Baz1b knock-out mice had significantly different skulls mainly as a results of 
reduction in the parietal and nasal bones as well as a relative hypoplasia of the lower jaw 
while the heterozygote mice had narrower and shorter craniums in comparison to the wild-
type mice along with reduced size of the posterior region of the lower jaw. Importantly, Baz1b 
expression is strongly up-regulated in all the major facial primordia from early in 
embryogenesis including the cranial neural crest-derived mesenchyme that drives facial 
morphogenesis. These results also suggest that BAZ1B could be important for cranial 
development (Ashe, Morgan et al. 2008, Yoshimura, Kitagawa et al. 2009).  
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Having said that, the most striking craniofacial abnormalities such as shorter cranial 
base and narrowing of the posterior part of the skull observed in mice lacking human proximal 
region spanning Trim50-Limk1. Importantly, no differences in cranial morphology of mice 
lacking the human distal region (Limk1–Gtf2i) were seen which is in contrast with the fact 
that in atypical WBS with distal deletion craniofacial features are more evident implying to 
the complexity and difference of craniofacial abnormalities in mice and human (Li, Roy et al. 
2009).  
All together, these studies further highlight the role of BAZ1B as a tantalizing 
candidate  since both in heterozygous knockout mice and in the context of larger deletion the 
phenotype were evident.  
2.3.4. Calcium abnormalities 
Ranging from severer (during infancy) to mild (in general), hypercalcemia can affect 
5-50 percent of the WBS patients. There is no confirmed mechanism for hypercalcemia in 
these patient however, various mechanism such as vitamin D sensitivity, increased 1,25-
dihydroxyvitamin D levels, and defective calcitonin synthesis or release have been suggested 
so far (Pober 2010). In line with the transient hypercalcemia seen in infants and children with 
WBS, heterozygous Baz1b mice showed elevated serum calcium levels (Yoshimura, Kitagawa 
et al. 2009).   
2.3.5.  Diabetes Mellitus 
In the recent studies it has emerged that majority of WBS patients suffer from diabetes 
Mellitus and that there is a high prevalence of impaired glucose tolerance among patients with 
Williams Beuren syndrome (Pober 2010).  
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Through the studies of the knockout mice models so far two genes has been implicated 
to play a role in glucose dysregulation. First, syntaxin 1A was shown to have a role in 
membrane vesicle fusion and pancreatic cell exocytosis of insulin granules, and more 
interestingly mouse models with altered STX1A expression levels showed significant 
alteration in glucose metabolism due to abnormal insulin secretion, nominating this gene as a 
important candidate for the observed phenotype in these patients. (Lam, Leung et al. 2005, 
Ohara-Imaizumi, Fujiwara et al. 2007). 
The second candidate which could be involved in metabolism of glucose in WBS 
patient is MLXIPL which is an element binding protein and regulate the expression of a liver 
enzyme responsible for the carbohydrate response synthesis of fatty acids and triglycerides 
(Iizuka and Horikawa 2008).  The elevated plasma glucose level in Mlxpl-null mice is in line 
with the phenotype observed in WBS patients, however, in contrast to WBS patients, Mlxipl-
null mice have reduced fatty acid synthesis and lowered fat deposition (Osborne 2010).  
2.4.7q11.23 duplication syndrome 
Although from the time the genetic basis for WS was discovered by Ewart et al., in 
1993,  there  was an assumption that there also could be a syndrome caused by a duplication of 
the WBS genetic interval, 7q11.23 duplication syndrome has emerged only recently and 
therefore the full clinical spectrum has not been discussed extensively (Ewart, Morris et al. 
1993, Somerville, Mervis et al. 2005). One reason for the fact that this syndrome remains 
often undiagnosed, could be since patients with duplications often have milder pathological 
consequences than the reciprocal deletions. Beside milder facial dimorphic abnormalities, the 
most striking features of 7q11.23 duplication is impairment in social interaction and 
communicative skills similar to autistic spectrum disorders and indeed there is an increased 
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prevalence of autism among these patients (Velleman and Mervis 2011).  The involvement of 
same genetic interval in these two 7q11.23 associated diseases, points out to small subset of 
dosage-sensitive genes affecting cognition, social behavior and communication skills.  
 
 
 
 
 
Fig.1.5 Three children who have 7q11.23 duplication syndrome, aged 2 years, 7 years, and 9 
years.  
(Adapted from (Velleman and Mervis 2011)) 
2.4.1. Facial characteristics 
So far facial dysmorphic features have been reported in all of 7q11.23 duplication 
cases. These craniofacial features include a broad forehead, high broad nose, neatly placed 
straight eyebrows. Moreover, short philtrum and thin lips are two distinctive features which 
are opposite to what observed in WBS patients (Fig 1.5). In addition, some authors have 
commented on a slight asymmetry of the face and macrocephaly that has been reported in a 
some cases (Somerville, Mervis et al. 2005, Berg, Brunetti-Pierri et al. 2007, Torniero, Dalla 
Bernardina et al. 2008, Van der Aa, Rooms et al. 2009, Merla, Brunetti-Pierri et al. 2010, 
Velleman and Mervis 2011)  
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2.4.2. Cardiovascular abnormalities and connective tissue involvement 
Cardiovascular abnormalities are not frequently reported and only affect around 20 
percent of people with 7q11.23 duplication. Beside ventricular and atrial septal defect, the 
most common problem so far was patent ductus arteriosus which is a failure in the closure of 
the channel between the aorta and the pulmonary artery that takes blood to the lungs (Merla, 
Brunetti-Pierri et al. 2010).  
2.4.3. Neurodevelopmental abnormalities 
Regarding the neurological problems, epilepsy (with the prevalence of 20 percent) and 
hypotonia are the most commonly reported ones. In line with the WBS patient, the brain MRI 
abnormalities have frequently been reported, however no consistent brain abnormalities have 
been reported so far (Torniero, Dalla Bernardina et al. 2008, Van der Aa, Rooms et al. 2009). 
In term of cognitive and behavioral profile, the majority of the patients are 
developmentally delayed with few exceptions with normal IQ (Van der Aa, Rooms et al. 
2009). 
Either expressive and/or receptive language delay has been seen in almost all patients. 
Such language impairment along with the spared of visuospatial cognitive skill in patient with 
7q11.23 duplication is in contrast with typical cognitive profile of the WBS patient. As 
discussed previously, WBS patients exhibit a relative strength in verbal skill and are severely 
impaired in visuospatial skills (Torniero, Dalla Bernardina et al. 2008, Pober 2010).  
Another important feature that has been noted in 7q11.23 duplication patients is 
deficits in social interaction including poor eye contact, poor social interaction, limited facial 
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expressions, repetitive behaviors and repetitive speech which are all considered as formal 
diagnosis of autism or autism spectrum disorder (Berg, Brunetti-Pierri et al. 2007, Van der Aa, 
Rooms et al. 2009).  
Recently, Osborne group has generated mice with varying numbers of Gtf2i copies. 
Interestingly, comparing to the mouse pups which are harboring one or two copies of GTF2i, 
pups with extra GTF2i copies exhibited increased maternal separation-induced anxiety 
(Mervis, Dida et al. 2012).  
2.5. Rationale and aims of the study 
Despite of such progress in understanding of the physiopathology of the 7q11.23 
associated disease, the attempts to correlate genotype with phenotype in WBS have been only 
moderately successful as they mainly relied on:  
2.5.1. Individuals with atypical deletions  
The identification of individuals with atypical deletions of the critical region in which 
only a subset of genes are hemideleted can be of immense value. However, these individuals 
are extremely rare and so far less than fifty individuals with such deletion have been 
identified. Moreover, the exact breakpoints of each deletion have not been established in many 
cases. In addition, the third major problem in this regard is that, these patients have not been 
evaluated by the same physicians and thus they have not been subjected to the same battery of 
clinical, cognitive, and psychological testing. More importantly, there's too much variability in 
phenotype between WBS patients (suggesting a high modulation of the phenotype due to the 
environment or remaining genetic background) to draw a conclusion from a single or a few 
case reports. (Merla, Brunetti-Pierri et al. 2010). 
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2.5.2. Generation of mouse models 
Several mouse models knocked-out for single WBS genes have been generated in 
order to understand the molecular basis of WBS. Out of the 26 genes deleted in WBS, so far, 
11 published mouse models exist most of which were generated through conventional gene 
targeting techniques in embryonic stem cells based on homologous recombination (Osborne 
2010).   
Although mouse models of WBS provide invaluable insight into the role of both 
individual and combinatorial gene disruption over a wide spectrum of analyses, however, they 
still cannot fully recapitulate human complex traits such as neurocognitive features. This is 
due to the fact that the primate cortex, and particularly the human cerebral cortex is different 
in several aspects from the rodents. For examples, there is a marked increase in the size of the 
cerebral cortex relative to the rest of the nervous system which could be the results of 
complexity and diversity of its developing stem cell populations (Shi, Kirwan et al. 2012). 
Regarding the musculoskeletal traits, mice are obviously quadripedal and thus these features 
will present differently than they might be in bipedal humans. Beside higher metabolic rate, 
earlier reproductive age and a far shorter lifespan than humans, mice have adapted to 
environments, predators and pathogens which are not true in the case of humans. These all 
could justify why it was anticipated that at least 20% of human important genes could be non-
essential in the mouse, which means that homozygously deletion in those genes will not result 
in lethality. And finally, comparing mice and human from genetic point of view there are 300 
genes which are unique to each species, making it impossible to study them in other organism 
(Osborne 2010).  
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Antonell et al. 2010  (GSE18188)
 Microarray of immortalized lymphoblasts
 4 typical WBS and 2 atypical deletions, each against 4 
age- and sex-matched controls
Reymond et al. 2011  (GSE16715)
 Microarray of fibroblasts
 8 typical WBS vs. 9 unmatched controls
Disease unaffected cells:
2.5.3. Cells and tissues from WBS individuals 
In terms of gauging WBS pathogenesis in human cells, so far two genome-wide 
transcriptomic analyses were performed, respectively on EBV-immortalized lymphoblasts or 
fibroblasts from WBS patients (Antonell, Vilardell et al. 2010, Henrichsen, Csardi et al. 2011). 
Our lab has performed a meta-analysis of these results starting from the re-evaluation of raw 
data, and found virtually no overlap between the sets of genes that were significantly 
deregulated in each study between WBS samples and controls, pointing to the acute need to 
generate meaningful, disease-relevant cell types from WBS patients (Fig1.6).  
 
 
 
 
 
Fig. 1.6 The Venn diagram showing the overlap of the differentially expressed genes from two 
transcriptomic data;  
fibroblast and immortalized lymphoblasts coming from WBS patient and healthy individuals. 
Bioinformatic analysis identifies no significant overlap between published transcriptomic 
studies pointing to the acute need for pathophysiologically meaningful cellular model.  
2.5.4.  iPSC-based technology as a platform for disease modeling 
Similar to any other scientific achievements, induced pluripotent stem cell technology 
was established on the basis of the various fundamental findings some of which have been 
summarized in Fig. 1.7.  Combination of all three streams of research enabled Shinya 
Yamanaka to design the experiments that lead to the identification of the factors which can 
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convent somatic cell to embryonic stem like state (Takahashi, Tanabe et al. 2007, Yamanaka 
2012). Briefly the generation of the tadpoles from unfertilized eggs that had received a nucleus 
from the intestinal cells of adult frogs reported in 1962 by John Gurdon could be considered as 
the first stream (Gurdon 1962).This finding were further consolidated by the generation of the 
first mammal through somatic cloning of mammary epithelial cells by Ian Wilmut and 
colleagues (Wilmut, Schnieke et al. 1997).  
The second stream was two seminal studies by two groups in the same year showing 
the role of the master transcription factors in inducing the formation of the legs and myocytes 
in Drosophila and fibroblast, respectively (Davis, Weintraub et al. 1987, Schneuwly, Klemenz 
et al. 1987) and finally, the third stream was the generation of mouse ESCs in 1981(Evans and 
Kaufman 1981, Martin 1981), further followed by establishment of the culture conditions that 
enabled the long-term maintenance of pluripotency by  Austin Smith (Smith, Heath et al. 
1988) and optimal culture conditions with basic fibroblast growth factor (bFGF) by James 
Thomson (Thomson, Itskovitz-Eldor et al. 1998).  
The first isolation of human embryonic stem cell by Thomson and colleagues in 1998 
provided the opportunity of deriving large quantities of differentiated cell types using defined 
growth factors (Thomson, Itskovitz-Eldor et al. 1998). Such a breakthrough was considered as 
an improved and reliable physiological models to study human developmental biology and 
drug discovery. Over the past decade various studies conducted to demonstrate the feasibility 
of using human pluripotent stem cells (PSCs) for these applications(Grskovic, Javaherian et al. 
2011). In spite of considerable advantages of ESC over routinely used immortalized or 
primary cells, ESC studies have faced to various issues. First, human ESC generated 
considerable ethical debates. Second only monogenic disorders could be studied as multifacto-
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rial disease cannot be screened through pre-implantation diagnostics (Grskovic, Javaherian et 
al. 2011). 
 Indeed, only nine years after Thomson’s work, the ground breaking study of Shinya 
Yamanaka demonstrated that human fibroblast cells can be converted to cells closely 
resembling ESC, so called induced pluripotent stem cells (iPSC)  only through ectopic over -
expression of four transcription factors namely;  OCT4 (also known as POU5F1), SOX2, 
KLF4 and MYC. The iPSC cells were not only similar to ESC in terms of morphology, 
growth characteristics but also were able to differentiate and form embryoid bodies in vitro 
and teratomas in vivo. More importantly, upon injecting iPSC into blastocysts they were 
capable to generate the entire animal showing that that iPSC similar to ESCs, possess full 
developmental potential (Takahashi, Tanabe et al. 2007). 
Fig. 1.7 Scientific streams led to or emerged from iPSC technology.  
A) Three scientific streams that led to the development of iPSCs. B) New scientific streams 
that emerged from the development of iPSCs. (Adapted from (Yamanaka 2012)).  
Soon after the initial report of mouse iPSCs, many group recapitulated the factor-based 
reprogramming in various systems and therefore new scientific streams have emerged from 
iPSC including cell replacement therapy, disease modeling and drug screening (Fig. 
1.7)(Yamanaka 2012). 
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iPSC based disease modeling has enhanced the study of disease mechanisms and 
therapies. Following the first report of human iPSCs in which came out a yeat afte mice 
report, the field of disease modeling based on iPSC technology was initiated by the generation 
of iPSCs using somatic cells derived from aged patients (Dimos, Rodolfa et al. 2008) and 
subsequently many other diseases were modeled so far (Park, Arora et al. 2008), (Grskovic, 
Javaherian et al. 2011, Inoue, Nagata et al. 2014). 
Identification of a disease-relevant cellular pathology is main goal in modeling any 
disease with iPSCs (Fig. 1.8). So far, modeling early onset diseases with strong genetic 
component and those with affect a highly defined cell or tissue type were the most compelling 
demonstrations (Ebert, Yu et al. 2009, Lee, Papapetrou et al. 2009, Marchetto, Carromeu et al. 
2010, Brennand, Simone et al. 2011, Nguyen, Byers et al. 2011, Consortium 2012). In 
addition, for some disease  with a known molecular mechanism such as spinal muscular 
atrophy or familial dysautonomia iPSC based assays which can capture relevant pathological 
mechanisms of the disease have been developed  and further subjected for small-molecule 
screening purposes in order to identify of new potential compounds (Ebert, Yu et al. 2009, 
Lee, Papapetrou et al. 2009, Grskovic, Javaherian et al. 2011). However, modeling more 
genetically complex disease such as sporadic Alzheimer’s disease or Parkinson’s disease still 
requires further studies for the identification of the cellular phenotypes that relate to known 
aspects of disease pathology (Grskovic, Javaherian et al. 2011).  
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Fig. 1.8 iPSC to model neurodegenerative and neurodevelopmental diseases.  
Human iPSC from neurologic patients and controls are generated after somatic tissue 
reprogramming (e.g. skin or blood cells). Neural progenitor cells (NPC) are generated and are 
further differentiated into neurons and/or glial cells. Neurons are then differentiated into 
subtypes of neurons such as dopaminergic, cholinergic, etc. Cellular phenotype is assessed by 
measuring neuronal morphology (i.e. process branching, spine density/size/maturation). Next, 
connectivity and circuitry integration can be analyzed by calcium influx transients, 
electrophysiology and transneuronal tracing with the rabies virus. In addition, the cross-talk 
between neurons and glia can be studied to tease out autonomous and non-autonomous aspects 
of the disease. Once a distinct disease-related phenotype is identified, drug-screening 
platforms can be developed to test compounds that improve cellular phenotype. Therapeutic 
compounds could emerge from the screenings, potentially benefiting neurologic patients 
(Adapted from (Marchetto, Winner et al. 2010) ). 
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To date, several disease phenotypes has been reported from patient-derived cells which 
have been used to recapitulate in vitro models of various disease Some of the key examples of 
neurological disease are discussed below: 
2.5.4.1.Spinal Muscular Atrophy 
Spinal Muscular Atrophy (SMA) is a neuromuscular childhood disease with an 
autosomal recessive inheritance pattern. SMA is the most common cause of death among 
heritable disease in infants and unfortunately there are no effective treatments available to 
date. A mutations in the SMN1 gene results in a decrease in the levels of the survival of motor 
neuron (SMN) protein which subsequently leads to motor neuron degeneration. Screening in 
patient derived irrelevant cells such as fibroblast has not yielded in any compound which can 
enter to the clinic probably due to the fact that the mechanisms that regulate SMN protein 
levels in non disease affected cells are substantially different from those in human motor 
neurons in vivo(Crawford and Pardo 1996, Grskovic, Javaherian et al. 2011).   
Ebert and colleagues generated two iPSC lines from a patient with SMA and an 
unaffected relative and differentiated them into motor neurons. Importantly, number of motor 
neurons was shown to be reduced in the cells derived from patients with SMA. This key 
experiment demonstrated for the first time that reprogramming and differentiation process can 
faithfully capture and recapitulate the disease phenotype. Although two compounds (valproic 
acid and tobramycin), were shown to increase the number of SMN-rich structures in the 
patient-derived iPSC, it remains to be seen whether these compounds can exhibit the same 
effect in motor neurons and thus rescue motor neuron loss in patients (Ebert, Yu et al. 2009, 
Grskovic, Javaherian et al. 2011).  
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2.5.4.2.Familial dysautonomia 
Familial dysautonomia is a disorder which affects the survival of sensory, sympathetic 
and parasympathetic neurons as a result of abnormal migration of neural crest cells. Like 
SMA, there are not any effective treatments or appropriate disease models for this disease. In 
majority of the patients it is caused by mutations in the gene encoding IκB kinase complex-
associated protein (IKBKAP) resulting in the skipping of exon 20 (Slaugenhaupt, Blumenfeld 
et al. 2001).  
Lee, Studer and colleagues derived iPSCs from three young patients with familial 
dysautonomia and subsequently differentiated those lines into neural crest cells. They found a 
defect in the migration and neurogenesis in the neural crest cells. Through an screening 
approach they found that kinetin can markedly reduce the splicing and neurogenesis defect in 
iPSC-derived neural crest cells of patients with familial dysautonomia. This study further 
confirmed the importance of iPSC-based cellular models for phenotypic screening and drug 
discovery (Lee, Papapetrou et al. 2009, Grskovic, Javaherian et al. 2011). 
2.5.4.3. Rett syndrome 
In another effort, Marchetto et al. focused on Rett syndrome, a developmental 
neurological disease which is part of the larger group of autism spectrum disorders. This 
syndrome is caused by mutations in methyl-CpG-binding protein, a protein involved in DNA 
methylation(Chahrour, Jung et al. 2008).  iPSCs generated from healthy controls and patients 
with Rett syndrome and then were differentiated into glutamatergic and GABergic neurons. 
By assessing neurogenesis, synapse number and neuronal morphology the authors did not 
observe any changes in neurogenesis. However, they were able to measure a substantial 
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reduction in synapse number as well as a reduction in the number of spines which were in line 
with previous reports observed in the post-mortem brains of patients with Rett syndrome. 
Further experiment using electrophysiology and calcium imaging showed that calcium 
oscillations and the frequency of spontaneous postsynaptic currents were decreased in the 
neurons of patients with Rett syndrome (Marchetto, Carromeu et al. 2010, Grskovic, 
Javaherian et al. 2011).  
2.5.4.4.Parkinson’s disease 
 Parkinson’s disease (PD) is caused by the progressive loss of midbrain dopaminergic 
neurons and it is considered as the second most common neurodegenerative disorder in the 
world. However, there is not any known cure for Parkinson’s disease, and neurodegeneration 
progresses leads to the worsening of symptoms and a loss of therapeutic efficacy. In two 
different attempts, patient-derived neurons from familial forms of Parkinson’s disease have 
been exploited to model disease in vitro (Grskovic, Javaherian et al. 2011, Nguyen, Byers et 
al. 2011, Seibler, Graziotto et al. 2011). 
In the first study Seibler and colleagues derived dopaminergic neurons from patients 
with mutations in the gene encoding PTEN-induced putative kinase 1, which is thought to 
regulate a protein that is associated with familial Parkinson’s disease,  parkin. Patient-derived 
dopaminergic neurons exhibited impaired recruitment of parkin to mitochondria, increased 
mitochondria copy number and increased expression of the mitochondrial regulator 
peroxisome proliferator-activated receptor-γ co-activator 1α. Strikingly, authers showed that 
these phenotypes could be rescued by exogenous expression of wild-type PTEN-induced 
putative kinase 1 (Grskovic, Javaherian et al. 2011, Seibler, Graziotto et al. 2011). 
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 In the second attempt Nguyen and colleagues generated iPSCs from a patient with the 
most common mutations familial Parkinson’s disease encoding leucine-rich repeat kinase. 
Patient-derived dopaminergic neurons showed increased vulnerability to stress by hydrogen 
peroxide, 6-hydroxydopamine and the proteasome inhibitor MG-132, in line with the previous 
findings that both genetic and environmental factors contribute to the development of 
Parkinson’s disease(Nguyen, Byers et al. 2011).  
2.5.4.5.Huntington’s disease 
Huntington’s disease (HD) is a neurodegenerative disorder with an autosomal 
dominant inheritance pattern. HD patients suffer from progressive motor dysfunction, 
cognitive decline, and psychological problems. HD caused by an expansion of 
polyglutamine(CAG) repeats in the huntingtin (HTT) protein and the age of onset for these 
symptoms is correlated with the number of repeats, where more than 36 repeats is considered 
a pathological threshold(An, Zhang et al. 2012). 
The HD Consortium reported a unique and well-characterized resource to elucidate 
disease mechanisms in HD through the generation and characterization of a large cohort of 
iPSC lines from HD patients and healthy controls. Importantly, microarray profiling revealed 
CAG-repeat-expansion-associated gene expression patterns that distinguish patient lines from 
controls, and early onset versus late onset HD.  iPSC derived  neural cells exhibited disease-
associated alterations in electrophysiology, metabolism, cell adhesion, and ultimately cell 
death for lines with both medium and longer CAG repeat expansions.  They also showed that 
lines harboring the longer repeats are the most vulnerable to cellular stressors and BDNF 
withdrawal, as assessed by a range of assays across consortium laboratories. The HD iPSC 
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collection provides a human stem cell platform for screening novel the 
therapeutics(Consortium 2012). 
2.5.4.6.Schizophrenia 
Schizophrenia (SCZD) is a genetic neurological disorder with a world-wide prevalence 
of 1%. The estimated inheritability of the disease is a 80–85%.  Post-mortem studies have 
revealed some abnormalities such as reduced brain volume, cell size, spine density and 
abnormal neural distribution in the prefrontal cortex and hippocampus of SCZD brain 
tissue(Wong and Van Tol 2003). Although, the neuropharmacological studies have implicated 
dopaminergic, glutamatergic and GABAergic as the main cell types affected in SCZD, the 
molecular mechanisms underlying the disease state remain unclear. The first utility of iPSC 
for such a complex genetic psychiatric disorder were reported by Brennand et al. where they 
probed  hiPSC based neuronal phenotypes and gene expression changes associated with 
SCZD. .They reprogrammed fibroblasts from SCZD patients into human induced pluripotent 
stem cells and subsequently differentiated these patient derived hiPSCs into neurons. In brief, 
SCZD hiPSC neurons exhibited diminished neuronal connectivity in conjunction with 
decreased neuritis number, PSD95-protein levels and glutamate receptor expression. 
Strikingly, following treatment of SCZD neurons with the antipsychotic loxapine, the main 
cellular and molecular elements of the SCZD phenotype were rescued (Brennand, Simone et 
al. 2011).  
2.5.4.7.Timothy syndrome 
Of the key examples of the iPSC based disease modeling for monogenic 
neurodevelopmental disorders were reported by Dolmetsch and his colleagues by modeling 
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Timothy syndrome which is caused by a missense mutation in the L-type calcium channel 
Cav1.2 that is associated with developmental delay and autism. They successfully generated 
cortical neuronal precursor cells and terminally differentiated neurons from induced 
pluripotent stem cells derived from patients with Timothy syndrome. Authors revealed that 
cells from these individuals have defects in calcium (Ca2+) signaling and activity-dependent 
gene expression, as well as abnormalities in differentiation, including decreased expression of 
genes that are expressed in lower cortical layers. Timothy syndrome derived neurons showed 
abnormal expression of tyrosine hydroxylase and increased production of norepinephrine and 
dopamine. Importantly, they could rescue the phenotype by treatment with roscovitine, a 
cyclin-dependent kinase inhibitor and atypical L-type–channel blocker2–4. These findings 
contributed significantly to understand how Cav1.2 regulates the differentiation of cortical 
neurons in humans and offered important insights into the causes of autism in individuals with 
Timothy syndrome (Pasca, Portmann et al. 2011). Despite of such a great reports, many issues 
regarding the utility and application of the iPSC cells has yet to be further elucidated some of 
which are discussed below: 
2.5.4.8. Safe, efficient and reliable protocol for generation of iPSC 
The historical and the most widely practiced method for generation of iPS is 
transduction of reprogramming factors via retro/lenti viruses. However, these methods are 
limited by: i) low efficiency of iPSC derivation; ii) the risk of insertional mutagenesis and iii) 
residual transgene expression from integrated vectors which may inadvertently affect the 
differentiation of iPSCs (Takahashi, Tanabe et al. 2007, Yu, Vodyanik et al. 2007, Warren, 
Manos et al. 2010). 
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To tackle these issues, numerous non-integrating platforms based on DNA, RNA, 
miRNAs, and proteins have been developed to generate integration-free iPSCs, and the 
advantages and drawbacks have been extensively discussed previously (Gonzalez, Boue et al. 
2011). Among these, RNA-based iPSC approaches using Sendai virus (Fusaki, Ban et al. 
2009), miRNAs (Anokye-Danso, Trivedi et al. 2012), and mRNA transfection (Warren, 
Manos et al. 2010) avoid integration associated problems and therefore appear safer methods 
for future clinical applications. 
Infection by Sendai virus has been recently used for the expression of pluripotency 
factors. Since it is a negative-sense, single-stranded RNA virus and does not go through a 
DNA intermediate, it can be considered as a highly efficient and integration free method for 
reprogramming (Fusaki, Ban et al. 2009, Ban, Nishishita et al. 2011). However, the main 
drawback of this method is that Sendai virus replicates in iPSC clones after reprogramming, 
therefore this approach requires a selection step followed by several passaging steps from the 
single-cell level to isolate virus-free iPSCs. Recently a temperature-sensitive mutant of Sendai 
virus has been introduced as a successful alternative method to remove the virus, though this 
method still requires a higher biosafety due to production of infectious virus particles (Ban, 
Nishishita et al. 2011, Yoshioka, Gros et al. 2013).  
In a more promising attempt, Warren et al. first described the ability to reprogram 
human cells using modified mRNA with conversion efficiencies and kinetics superior to 
DNA-based methods. This approach involves the daily transfection of five individual mRNAs 
(OCT4, SOX2, KLF4, CMYC, and LIN28) over the 14-days reprogramming period. This 
technology was a major leap forward to safely and effectively reprogram human cells 
(Warren, Manos et al. 2010). 
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Conventional virus based method miRNA/mRNA based approach
Low efficiency (0.01-0.1) High efficiency (0.5)
Takes almost 30 days Rapid reprogramming (10 days)
Integration of virus cassette Eliminates the risk of genomic integration
Viral mediated insertional mutagenesis Virus free
Hampering differentiation potency of iPSC No need for virus excision or silencing
Need  inactivated MEF layer Eliminate adaptation steps
Refractory samples Reprogramming recalcitrant samples
The impact of specific microRNAs on the promotion of induced pluripotency had 
previously been demonstrated. While the work of Anokye-Danso et al. relied on integrating 
lentiviral vectors to express miRNA clusters for the efficient derivation of iPSC, Miyoshi et al. 
were able to deliver synthetic miRNA to successfully reprogram somatic cells, albeit at a low 
efficiency (Miyoshi, Ishii et al. 2011, Anokye-Danso, Trivedi et al. 2012).  
In a very fruitful collaboration with Stemgent and by combining miRNA and mRNA 
reprogramming approaches, I established a non-integrative reprogramming system that is 
faster, easier and applicable to reprogramming a range of patient samples and for which I was 
selected for the spotlight program of this technology’s leading provider 
(https://www.stemgent.com/campaigns/interview_with_sina_atashpaz). The inclusion of 
microRNAs cocktail (microRNA Booster Kit, Stemgent) in addition to the 5 factor mRNAs 
cocktail, accelerates the process to less than two weeks and supports the reprogramming of 
patient fibroblasts that are refractory to other methods. The removal of a feeder layer from the 
reprogramming process improves the visibility of morphological changes occurring in the 
target cells. The main advantage of the miRNA enhanced reprogramming method over the 
mRNA based method is shown in Fig. 1.8. The efficacy of the different protocols for 
generation of the iPSC is also shown in Fig. 1.8. 
 
B A 
C 
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Fig. 1.9 A) Comparison of standard reprogramming methodologies.  
mRNA proves to be the most efficient and safe reprogramming method as compared to all 
viral/DNA-based methods B) Comparison of conventional virus based reprogramming 
methods with miRNA enhanced reprogramming approach. C) RNA reprogramming 
experimental timelines compared to other reprogramming systems. 
 (Adapted from Stemgent mRNA Reprogramming System manual, 
http://assets.stemgent.com/files/1357/original/RNAReprogrammingProductSheet_final-
full.pdf). 
2.5.4.9.Variations in iPSCs 
Genomic and epigenomic variabilities across reprogrammed iPSC lines have been 
recently recognized as a key concern for iPSC-based cell replacement therapy, disease 
modeling and drug discovery. In terms of disease modeling and drug discovery this could 
invite caution in the interpretation of results from few lines that do not adequately sample 
variability either across individuals or across lines reprogrammed from the same individual.  
The sources of such variability could be investigated at three levels: I) variability in the 
criteria that define iPSC lines as pluripotent cells, II) variability in cell lines from different 
donors (cell line variability due to different genetic backgrounds), and III) variability in cell 
lines from the same donor (clone variability due to the stochastic nature of the reprogramming 
method) (Vitale, Matigian et al. 2012, Liang and Zhang 2013). Many studies have recently 
tried to investigate the source of variability within each level. However, the precise 
contribution of each of the involved element has not been studied in a comprehensive study. 
This could be in part due to complexity and unknown mechanism of reprogramming process. 
More importantly such variations could be the results of the various parameters such as 
genetic and epigenetic alterations which can be involved at different level of the programming 
process. Among the genetic variations, aneuploidy, subchromosomal copy number variation 
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(CNV), and single nucleotide variations (SNVs) are the main ones while variations in X 
chromosome inactivation, variations in local epigenetic status (e.g., histone modification and 
DNA methylation) are considered as the key epigenetic variation that exists in PSC and as 
mentioned earlier, these variations could originate from different stages during the 
reprogramming process such as starting cells, during reprogramming and  finally during 
passaging and culturing iPSC cells (Fig. 1.9) (Cahan and Daley 2013, Liang and Zhang 2013).  
 
 
 
 
 
 
 
 
 
 
Fig. 1.10 Genetic and epigenetic variations and their causes, functional consequences, and 
impacts on applications iPSCs  
derived from transcription factor (TF)-mediated reprogramming may bear different types of 
genetic (blue boxes) or epigenetic (purple boxes) variations that can be introduced from varied 
sources (gray boxes) during the derivation and manipulations of iPSCs. These variations may 
lead to different functional consequences (red boxes) that need to be considered when iPSCs 
or their derivatives are used for applications (green boxes). Solid lines, reported or definite 
connections; dotted lines, potential connections (Adapted from (Liang and Zhang 2013))  
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So far, two main methods have been suggested to reduce these variations. One is to 
minimize the epigenetic and genetic variation and the second one is the extensive 
characterization of each given iPSC line in order to exclude the lines which do not fell into the 
iPSC categories. Regarding the first criteria, reprogramming cells with the minimum genetic 
accumulation should be taken into the account. Moreover, non-integrating methods for the 
introduction of pluripotancy factors which can protect the genomic integrity and maintain 
epigenetic fidelity during reprogramming could be applied and finally, inclusion of some 
chemical that has also been shown to hamper the epigenetic aberrancy in iPSC shown to be 
useful.  In terms of the second solution that is the careful monitoring and characterization of 
the variations a wide range of the analysis can be performed ranging from the basic 
characterizations such as karyotyping and expression analysis of the pluripotancy markers to 
the functional analysis including embryoid body and teratoma formation. In addition, more 
sophisticated and comprehensive analysis like genome-wide sequencing, expression analysis, 
and DNA and histone modification analysis could be exploited for genetic and epigenetic 
profiling of iPSC lines (Cahan and Daley 2013, Liang and Zhang 2013). 
2.5.4.10. Differentiating hiPSCs to disease affected cell types  
So far, most of the disease phenotype has been observed only in lineage differentiated 
cell types and not in iPSC. Therefore, gaining information on the pathogenesis of diseases 
could be mostly possible through the reliable differentiation protocols which enable the 
differentiation of the iPSC toward disease relevant cell types (Saha and Jaenisch 2009). 
During the past years differentiation of the iPSC into various cell types has already been 
achieved:  neural progenitors (Chambers, Fasano et al. 2009), cortical neurons (Shi, Kirwan et 
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al. 2012, Shi, Kirwan et al. 2012), hepatocytes (Sullivan, Hay et al. 2010), blood cells (Choi, 
Yu et al. 2009), and neural crest(Lee, Chambers et al. 2010, Menendez, Kulik et al. 2013).  
In order to better recapitulate the differentiation events in the developing embryo, most 
of these protocols take advantage of the small molecules and morphogens that were shown to 
be involved in development in vivo and can have either agonistic or antagonistic role in 
signaling pathways. Such molecules need to be used in specific concentration, sequence and 
correct time frame to induce the stepwise progression through a developmental program (Fig. 
1.10). To achieve this goal, some protocols has exploited an alternative method in which they 
co-culture the target cells with the other cell types producing important factor to facilitate the 
differentiation process (Menendez, Kulik et al. 2013).  
 
 
 
 
 
Fig. 1.11 Pathways for generating cortical excitatory neurons from pluripotent cells in vivo 
and in vitro.   
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Pluripotent cells of the inner cell mass in the embryonic blastocyst are thought to differentiate 
into cells of the anterior neuroectoderm in the absence of any instructive signals through a 
series of default fate decisions. Shown in red are morphogens that promote alternative 
differentiation fates. Shown in green are factors that inhibit those morphogens and facilitate 
the default pathway. (Modified from (Hansen, Rubenstein et al. 2011)). 
 
Given the importance of the cerebral cortex in diseases such as epilepsy, autism and 
alzheimer’s disease, the generation of the cortical neurons from iPSC is of great interest. 
However, the establishments of a protocol which can give rise to the various cell types within 
cortex need a deep understanding of this system.  The cerebral cortex is composed of two 
main classes of neurons:  the majority (80%) is excitatory glutamatergic projection neurons 
that are generated by various pools of cortical stem and progenitor cells.  In brief, during early 
stages of neocortical development, neuroepithelial cells divide symmetrically to expand the 
progenitor pool before differentiating to radial glial cells (RGCs). RGCs however, divide 
asymmetrically not only to self-renew but also to produce either neurons or intermediate 
progenitor cells (IPCs). IPCs undergo symmetrical cell division to generate neurons, or 
additional IPCs. Basal RGCs (bRGCs) are similar to RGCs  as they have a basal attachment at 
the pial basement membrane, but in contrast , do not maintain an apical process and thus have 
their cell bodies located in the outer margins of the SVZ. bRGCs also self-renew and generate 
IPCs and neurons. Interestingly, at the end of neurogenesis, RGCs and bRGCs transform into 
astrocyte progenitors (Fig. 1.12) (Franco and Muller 2013). Finally, cortical stem cells are 
believed to generate the six layers of the adult cortex in a stereotyped temporal order, with 
deep layer neurons being produced first and upper layer neurons being produced last. Of note, 
cortical neurogenesis lasts over 70 days in human while it takes only 6 days in mice (Shi, 
Kirwan et al. 2012, Franco and Muller 2013).  
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The second class of the cortical neurons are GABAergic interneurons (about 20%) that 
are generated outside of the cortex and migrate in during development.  One of the major 
problems in generating cortical neurons is the reliable reproduction of the complex stem and 
progenitor cell populations found in the cortex in vivo. This is specially true because  as 
discussed above, although neuroepithelial ventricular zone cells are the primary stem and 
progenitor population of the cerebral cortex, there are at least two secondary progenitor cell 
populations which have been identified in mouse, ferret and humans namely; basal progenitor 
cells and outer radial glial cells (oRG) (Fig. 1.11 A).  All these groups of stem and progenitor 
cells appear to generate projection neurons.  In addition the contribution of the oRG cells to 
increased size of the human cortex and diversification of the upper layer neurons has been 
proposed in recent studies (Franco and Muller 2013).  On the basis of our current 
understanding of cerebral cortex development the Livesey group took advantage of two small 
molecules (i.e., SB431542 and Noggin) to  inhibit Smad signaling pathway and  developed a 
robust and efficient protocol that recapitulates crucial stages in human cortical development 
from PSC. This protocol consists of three  main steps i) the directed differentiation of human 
PSCs to diverse population of cortical stem and progenitor cells, ii) an extended period of 
cortical neurogenesis, iii) a late phase of neuronal terminal differentiation to acquire mature 
electrophysiological properties, synaptogenesis and network formation (Fig 1.11B). More 
importantly, unlike differentiation of mouse ES cells, the diversity of cortical projection 
neurons in this system is roughly equal in terms of the deep (early born) and upper (late born) 
layer neurons (Shi, Kirwan et al. 2012, Shi, Kirwan et al. 2012). 
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Fig. 1.12 Subtypes of stem and progenitor cells in the developing neocortex.  
A) A Schem Showes the diversity of the stem and progenitor cell during cortical embryonic 
development which undergo severl symetrical and asymetrical cell division to generate wide 
range of lower and upper layer neurons. Adapted from (Franco and Muller 2013)  
B) Schematic of the cortical differentiation protocol reported by the Levisey group through the 
combination of dual SMAD inhibition, combined with retinoids which is able to differentiate 
PSCs to cortical stem and progenitor cells that can be expanded/maintained with FGF2. The 
removal of FGF2 differentiate Pax6-expressing radial glia, Tbr2-expressing basal progenitor 
cells and Pax6+/Tbr2- outer radial glia (oRG) cells into lower layer neurons generated early, 
beginning around day 21 and upper layer neurons generated last, continuing beyond day 90. 
(Modified from (Shi, Kirwan et al. 2012)).  
 
In a different attempt, Menendez et al. developed a highly efficient, lineage-specific 
differentiation of human pluripotent cells to NCSC fate which can be applied to the modeling 
of neural crest–related human diseases (Menendez, Kulik et al. 2013).  Neural crest stem cells 
are a transient population arising from the neural plate border which upon delamination from 
the roof plate can migrate to different regions of the embryo and accordingly differentiate into 
a wide range of cell types such as sensory neurons, Schwann cells, melanocytes, cells that 
make up the craniofacial structures such as bone and cartilage and finally smooth muscle cells 
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that contribute to the heart valves (Lee, Chambers et al. 2010, Menendez, Kulik et al. 2013) 
(Fig. 1.12) . To this aim, the authors combined Smad inhibition with activation of the Wnt 
pathway to develop a single-step, highly efficient method for the generation of NCSCs from 
hESCs and hiPSCs. The key advantages of this method are that first, unlike previously 
described methods, this protocol does not require a co-culture on feeder layers to generate 
neural crest. Second, the efficiency of this protocol is very high and therefore does not require 
FACS sorting to obtain enriched populations and finally the generated NCSC using this 
method has been shown not only to have self-renewal potential upon freezing, thawing and 
multiple passaging but more importantly they can be differentiated into a wide range of 
differentiated cell types including smooth muscle cells, adipocytes, chondrocytes, osteocytes 
and peripheral neurons (Menendez, Kulik et al. 2013).  
 
Fig. 1.13 Embryonic development of neural crest stem cells.  
After neurulation neural crest cells migrate out and differentiate into multiple cell types like 
peripheral neurons, adipocytes, smooth muscle cells and Schwann cells. adapted from 
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http://web.biologie.uni-bielefeld.de/cellbiology/index.php/research/neural-crest-derived-stem-
cells 
Taking advantages of two key establishments that I have implemented in the lab 
namely mRNA based reprogramming and neural differentiation protocol,  in my PhD project, 
I aimed to understand two key questions in the context of modeling 7 q11.23 copy number 
variation among large cohort of samples:   i) the extent to which early developmental lineages 
are informative about disease-relevant pathways affected by genetic mutations and, ii) the 
feasibility of reliably identifying those pathways beyond the sources of variability inherent to 
the iPSC-based approach.  
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3. Materials and Methods 
 
3.1. Human samples 
Participation in this study by patients and relatives along with skin biopsy donations 
and informed consent procedures were approved by the Ethics Committee of the Genomic and 
Genetic Disorder Biobank (Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy) and 
the University of Perugia (Azienda Ospedaliera-Universitaria "S. Maria della Misericordia", 
Perugia, Italy). 
3.2. Fibroblast culture and reprogramming 
Primary fibroblast cell lines WBS1-2-3-4, 7Dup-ASD2, AtWBS1, CTL1R were 
obtained from Genetic Disease Biobank. 7Dup-ASD1 primary fibroblast was obtained from 
Azienda Ospedaliera-Universitaria "S. Maria della Misericordia", Perugia, Italy. Fibroblasts 
were cultured in HF medium composed as follows: RPMI 1640, 1% L-Glutamine, 1% Pen-
Strep, 15% FBS for few passages before reprogramming. 
WBS1-2-3-4, 7Dup-ASD1-2, AtWBS1, CTL1R, and CTL2 fibroblast lines were 
reprogrammed using mRNA Reprogramming Kit (Stemgent) with some modifications. 
Briefly, 4-5x106 million newborn foreskin fibroblast cells (NuFF) (Stemgent) were plated 
onto a 75-Tflask with Plurition media (Stemgent) over 8 days and media collected daily and 
used as condition Pluriton media during reprogramming. Next, target fibroblast cells were 
plated at different cell densities (5000-10,000) onto already Nuff plated plates. Cells pre-
incubated with B18R (Stemgent) and transfection with the mRNA cocktail (OCT4, KLF4, 
CMYC, LIN28 and SOX2) along with nuclear GFP (Stemgent) were perform daily for about 
16 days.   For reprogramming 7Dup-ASD2 and CTL1R lines, microRNA Booster Kit 
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(Stemgent) were used to enhance the reprogramming. To this goal, I followed the mRNA 
reprogramming protocol with the following modifications: i) Target cells were plated onto 
matrigel coated plates instead of NuFF cells. ii) Target cells were plated at higher cells 
densities i.e., 5-10x104. iii) Cells were transfected with miRNA cocktail (Stemgent) at day 1 
and 5 of reprogramming.   CTL3 and WBS2 line was reprogrammed using STEMCCA 
polycistronic lentiviral vector CTL3 underwent cre-mediated excision of the integrated 
polycistron. For mRNA-mediated reprogramming epithelial-to-mesenchymal transition was 
monitored from day 5 by tracing GFP-positive cells. Successfully reprogrammed colonies 
were assayed for pluripotency at day 20 using a live TRA-1-60 antibody (Stemgent) and 
selected for further expansion as detailed below. All cells culture at low O2 tension (5%). 
3.3.iPSC culture 
iPSC lines were cultured on mitomycin C-inactivated mouse embryonic fibroblasts 
(MEFs) as previously described (Takahashi, Tanabe et al. 2007) in a medium composed as 
follows: DMEM-F12 (Gibco) in a 1:1 ratio supplemented with 20% KSR, 1% Non Essential 
Amino Acids, 1% Pen-Strep, 1% Glutamine, 0.1 % beta-mercaptoethanol, 10 ng/ml basic 
fibroblast growth factor (bFGF, Gibco). Colonies were passed and expanded twice by physical 
fractionation with a sterile needle and re-plated onto newly seeded MEFs for line 
establishment. After few passages iPSCs were adapted to grow in feeder-free condition on 
plates coated with human-qualified Matrigel (BD Biosciences) diluted 1:40 in DMEM-F12 
and in mTeSR-1 (StemCell Technologies) medium and were passed by physical fractionation 
upon a 2 minutes treatment with Dispase (Sigma) at 37°C. Feeder-free iPSCs were also 
adapted to grow in single cell culture by dissociating them by a 3 minutes treatment with 
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Accutase (Sigma) at 37°C and finally resuspended in a suitable volume of mTeSR-1 
supplemented with 5 μM Y-27632 (Sigma).  
3.4.Teratoma assay and immunohistochemistry 
Teratoma assay was performed by subcutaneously injecting 1-3x106 iPSCs in human-
qualified Matrigel (BD Biosciences) into the dorsal flanks of NOD-SCID IL2RG male mice. 
Teratomas were isolated when the diameter reached > 1.5 cm and fixed in 4% buffered 
formalin. Samples were then OCT embedded, sectioned and stained for H&E and germ layer 
specific antibodies: desmin (Dako), S-100 (Dako) and cytokeratin (Dako). 
3.5. Immunocytochemistry 
Cells were fixed in 4% PFA for 20’ and subsequently blocked in 10% FBS + 0.1% 
Triton for 30’ at room temperature. Cells were incubated with primary antibodies overnight at 
4°C and then with secondary antibodies for one hour at room temperature. Primary and 
secondary antibodies were resuspended in 10% FBS. Primary antibodies used were OCT3/4 
(SantaCruz), NANOG (Everest Biotech), SSEA3 (Invitrogen), Tra1-60 (Stemgent), TBR2 
(Abcam), SOX2 (R&D), PAX6 (HBDS), NESTIN (Abcam), FOXG1 (StemCulture), ZO1 
(Invitrogen), OTX2 (Millipore), Ki67 (Abcam), PHH3 (Millipore), CLIP2 (Abcam), BRN2 
(Santa Cruz), TUJ1 (Covance), vGlut1 (Synaptic systems), MAP2 (Covance), vGLUT2 
(Synaptic System), GAD67 (Millipore),  Cux 1(Santa Cruz), Satb2 (Abcam), TBR1 (Abcam), 
GFAP (DAKO). Alkaline phosphatase staining was performed using Alkaline Phosphatase 
Detection Kit (Sigma). Images were acquired at an Olympus AX70 microscope. 
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3.6.DNA, RNA and protein extraction 
Genomic DNA was extracted from fibroblasts and feeder-free iPSC lines using the 
DNeasy Blood and Tissue Kit (Qiagen) according to manufacturer specifications. 
RNA was extracted from iPSC lines using the RNeasy Micro Plus Kit (Qiagen) according to 
manufacturer specifications, substituting the genomic DNA elimination column by needle and 
Dnase treatment (Qiagen). Quality and concentration of DNA and RNA was assessed using a 
NanoDropSpectrophotometer (NanoDrop Technologies). 
Proteins were extracted as follows: cells were scraped from the plate and centrifuged at 
1100 g at 4°C for 3 minutes, then washed in PBS and lysed in RIPA buffer plus protease 
inhibitors cocktail (Sigma) on a spinning wheel at 4°C for 30 minutes. Lysates were sonicated 
using the Bioruptor Sonication System (UCD200) for 3 cycles of 30 seconds with 60 seconds 
breaks at high power. Lysates were centrifuged at 13000 g for 15 minutes and supernatants 
were transferred to a new tube. Protein quantification was performed using the Bradford 
protein assay (BioRad) and following manufacturer instructions. 
3.7. Immunoblotting 
For immunoblotting 20 to 40 μg of protein extract per sample were run on a precast 
Nupage 4-12% Bis-tris Gel (Life Technologies), transferred on a nitrocellulose membrane and 
blocked in TBS-T and 5% milk. Antibodies used for detection were GTF2I (Cell Signaling), 
BAZ1B (Abcam) and GAPDH (Abcam), OCT3/4 (SantaCruz). Blots were scanned using a LI-
COR Odyssey Infrared Imaging System and bands were quantified using ImageJ software. 
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3.8. RNAseq and Nanostring 
Library preparation for RNA sequencing was performed using Poly-A, RiboZero and 
Single Stranded kits (Illumina) according to manufacturer instructions. 
Nanostring quantification was performed according to manufacturer instructions and 
data normalization was performed using the nSolver Analysis Software 1.1. 
3.9. RNAseq analysis 
Reads were aligned to the hg19 transcriptome using TopHat 2.0.10. The alignment was 
first performed on the RefSeq transcriptome and all the reads that had an edit distance ≥ 1 
were realigned on the genome, allowing a maximum read edit distance of 3 and 3 (100 bp 
reads) and 2 (50 bp reads) maximum mismatches. 50bp stranded reads were analyzed using 
the “fr-firststrand” option. Quantification of reads over the RefSeq transcriptome was 
performed with Cufflinks 2.2.1 using sequence-bias and multi-read corrections. Differential 
gene expression was estimated using Cufflinks 2.2.1, using per-condition dispersion models. 
For the iPSC stage, given the presence of both polyA and Ribo-zero samples, we 
considered the union of DEGs identified through a global analysis of all samples (FDR < 0.05) 
with those identified through independent analysis of the polyA and Ribo-zero samples. In the 
latter case, we considered as differentially expressed genes that had a FDR < 0.2 in both 
datasets (comparing the same genotypes), and for which the change was in the same direction. 
3.10. Down sampling test 
The majority of differentially-expressed genes identified in this study were still found 
when removing the external controls, and most of the remaining DEGs were close to 
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significance, arguing against the introduction of a major bias through the use of external 
controls. 
In order to assess the effect, on the transcriptional analysis, of having fewer samples, 
we repeated the analysis of our polyA dataset (focusing on the comparison for which we had 
the most samples, i.e. the global analysis of WBS vs CTL iPSC), using only subsets of the 
samples. Random removal of 1 clone per patient lead to a dramatic reduction in the number of 
DEGs (48 to 76% lost), and to the identification of DEGs that are falsified by the discarded 
data. The impact of removing all clones from one patient per condition (amounting to fewer 
samples than removing one clone per patient) was even greater. In contrast, depth of 
sequencing appeared to make little difference: reducing coverage by half led to the loss of 
11% of DEGs and to very few false positives. 
3.11. Shuffling tests 
To assess the possibility that the observed differential expression might arise due to 
random variations, we performed a series of differential expression analysis between 
randomly-selected samples, discarding comparisons in which the two groups were not 
balanced for sex and/or genotype. A minimum of 3 such combinations were tested per tissue, 
and the resulting genes were pooled for the purpose of enrichment analysis. 
At the iPSC stage (using the polyA dataset), we first randomly assigned all patients to 
two groups, but we could obtain statistically significant genes in none of the combinations. 
We therefore gradually removed patients until significant genes were obtained, which did not 
happen until a comparison involving 6 vs 6 samples (in each group, 3 samples from 2 
patients). In contrast, when clones were selected and assigned to groups in a way that 
maximized the number of patients represented in each group, we had to go down to 3 vs 3 (3 
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samples per group, coming from 3 different patients) to get statistically significant genes (18 
DEGs, showing no significant GO enrichment). Similarly, random allocation of the control 
samples (including external controls, balanced across groups) yielded very few DEGs 
(maximum 17) and no significant GO enrichment. 
These results suggest that the primary source of “spurious” differential expression is 
genetic variation between individuals, which only gets mitigated using lines derived from 
several patients. 
Finally, it is interesting to note that despite yielding very few DEGs (maximum 78), 
some of the 6 vs 6 comparisons showed statistically significant enrichment for the GO 
categories of extracellular matrix organization and extracellular structure organization, 
pointing to these genes as particularly varying in expression between lines and/or individuals. 
In differentiated cell types, shuffling tests using (3 combinations of) 3 vs 3 samples 
yielded either no significant differential expression (NCSC), or very few genes (NPC) that 
displayed no significant enrichments, with the exception of the MSC dataset. The union of 
genes found significant from random combinations of the MSC samples showed several GO 
enrichments, including (albeit at a lower level) some categories that were found significant 
between the genetic conditions. However, removal of these genes did not significantly alter 
the main categories enriched among the DEGs between genetic conditions. 
3.12. cDNA preparation and qPCR 
Retrotranscribed cDNAs have been obtained from 1 μg of total DNA-depleted RNA 
using the superscript VILO retrotranscription kit from Life Technologies according to 
manufacturer instructions. 
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For real time q-PCR analysis a total amount of cDNA corresponding to 5 ng of starting 
RNA has been used for each reaction. FAST SYBR green master mix from Life Technologies 
and 10 μM primers pair have been used. The qPCR reactions have been performed on an 
Applied Biosystems® 7500 Real-Time PCR machine following the standard amplification 
protocol. 
The pair oligos used for qPCR were: GAPDH (F: GCACCGTCAAGGCTGAGAAC, 
R: AGGGATCTCGCTCCTGGAA), SOX10 (F: CTTCATGGTGTGGGCTCAG, R: 
GCTTGTCACTTTCGTTCAGC) and GTF2I (F: GATCTTGCAACCCTGAAATGG, R: 
CACCTGGAGATAGTATTGACCTG). SOX9 (F: CACAGCTCACTCGACCTTG, R: 
ACACAAATGTCCAAAGGGAATTC). ZIC1 (F: CCTACACGCATCCCAGTTC, R: 
TTGTGGTCGGGTTGTCTG). TFAP2 (F: GTTACCCTGCTCACATCACTAG, R: 
TCTTGTCACTTGCTCATTGGG). NGFR (F: GTGGAGAGTCTGTGCAGTG, R: 
ATCGGTTGTCGGAATGTGG). ELN (F: CCTGGCTTCGGATTGTCTC, R: 
CAAAGGGTTTACATTCTCCACC). 
3.13. Lentivirus production 
Production of STEMCCA and FOXG1 lentiviral particles was performed as previously 
described (Sommer, Stadtfeld et al. 2009). Briefly, plasmids expressing viral proteins GAG, 
POL, REV, TAT, and the vesicular stomatitis virus envelope glycoprotein (VSV-G) were co-
transfected with STEMCCA vectors into semi-confluent 293T cells by calcium phosphate 
precipitation. For the Syp-GFP production second generation packaging system (PAX and 
VSV-G) were used. For Supernatant of transfected cells were collected every 12 hours during 
2 consecutive days and concentrated by centrifugation. Viral particles were resuspended in 
iPSC medium and either used freshly for infection or frozen at −80°C. 
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3.14. Differentiation 
Differentiation of iPSC cells toward cortical neurons were carried out based on the 
previously published protocol (Brennand, Simone et al. 2011). Differentiation into the dorsal 
telencephalic lineage was accomplished by dual Smad inhibition in the presence of SB431542 
(Tocris) and Noggin (R&D) (Shi, Kirwan et al. 2012, Shi, Kirwan et al. 2012) with some 
modifications. Briefly, iPSC cells were adapted to single cells culture and plated at the optimal 
cells density onto matrigel coated plates to have 90% confluency the next day. Cells were 
treated with the inhibitors for 10-12 days and then re-plated using Dispase to initiate the 
formation of rosette like structures. Next, cells were splitted using Accutase to re-plated onto 
polyornitin-laminin coated plated at the right cell density for terminal differentiation.  iPSC 
Differentiation of NCSC and MSC was performed as previously described (Menendez, Kulik 
et al. 2013), through the activation of Wnt signalling and Smad pathway blockade by 
administering the small molecules GSK3i (Calbiochem) and SB431542 (Tocris). 
3.15. Flow cytometry 
1x10
6
 cells were fixed in 4% PFA and subsequently blocked in 10% BSA. Cells were 
incubated for one hour with primary conjugated antibody resuspended in 1-2% BSA. The 
primary conjugated antibodies used were CD57-FITC (HNK1, BD), CD271-647 (NGFR, 
BD), CD44-APC (EBIOS) and CD73-PE (BD). Analysis was performed on FACSCalibur 
(BD Biosciences) and data were analyzed with FCS express software (Tree Star Inc.). 
3.16. CGH array 
DNA was isolated from parental fibroblast and iPSC using Qiagen kit as described 
above. DNA concentration and purity were determinate with a ND-1000 spectrophotometer 
(NanoDrop Technologies, Berlin, Germany) while whole-genome copy number variations 
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(CNVs) analysis was carried out using the CytoScan HD array platform (Affymetrix, Santa 
Clara, CA). The CytoScan HD assay was performed according to the manufacturer protocol, 
starting with 250 ng of DNA. Briefly, total genomic DNA was digested with a restriction 
enzyme (NspI), ligated to an appropriate adapter for the enzyme and subjected to PCR 
amplification using a single primer. After digestion with DNase I, the PCR products were 
labeled with a biotinylated nucleotide analogue, using terminal deoxynucleotidyl transferase 
(TdT) and hybridized to the microarray. Hybridization was carried out in the Hybridization 
Oven 645 while subsequent washing and staining were performed using the Fluidics Station 
450.  
3.17. CGH array analysis 
Each array was then scanned with the Scanner 3000 7G and both quality control step 
and copy number analysis were performed using the Chromosome Analysis Suite Software 
version 2.0: i) the raw data file (.CEL) was normalized using the default options; ii) an 
unpaired analysis was performed using as baseline 270 HapMap samples in order to obtain 
Copy numbers value from .CEL files while the amplified and/or deleted regions were detected 
using a standard Hidden Markov Model (HMM) method. 
3.18. Microarray 
Microarray analysis was performed with the Affy package using Marc Carlson’s 
Hugene 2.1st RefSeq annotation file, version 18. Background normalization was performed 
using the RMA method, whereas between-sample normalization was performed using the 
quantile normalization method. Quantification of expression was obtained using perfectly 
matching probes only with median polish summarization.  Probe sets not assigned to known 
genes or having log2 fold changes < 0.5 were discarded and differential expression was 
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assessed using a 2-tailed t-test. For the purpose of enrichment analyses, DEGs with a FDR < 
0.2 were considered. 
3.19. Gene ontology enrichment analysis 
For RNAseq data, enrichment analysis was performed using the R package GO seq in 
order to correct for transcript length bias considering only categories with at least 10 annotated 
genes and discarding categories that had less than 8 significant genes.  
For genes measured by other methods, the enrichment analysis was performed with the 
package TopGO using the classic algorithm and Fisher’s test with the same cutoffs described 
above. In order to create enrichment treemaps, parent categories that had enriched children 
were first removed and then maps were created with the package Treemap, using as colors the 
combination of non-overlapping parent categories accounting for the largest proportion of 
plotted categories. All reported FDR values were calculated using the Benjamini-Hochberg 
method. 
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4. Results 
4.1. Recruitment of a large cohort of WBS and 7dupASD patients 
In collaboration with the Genomic and Genetic Disease Biobank 
(http://www.telethon.it/en/scientists/biobanks) supported by the Telethon foundation, we 
selected a unique combination of skin fibroblast from a large cohort of patients affected by 
WBS and 7dup-ASD along with the fibroblasts from their healthy relative as half matched 
controls (Table1) in one case as in the absence of disease-specific iPSC lines with isogenic 
controls, such control iPSC lines from unaffected parents are essential for identifying relevant 
phenotypes. Patients were assessed by a multidisciplinary team of specialists for a detailed 
record of clinical, functional, behavioral information (Tab. 3.1).  This cohort includes: i) five 
patients carrying the typical WBS deletion; ii) one patient carrying an atypical WBS deletion 
that spares several genes including BAZ1B, who exhibits milder craniofacial dysmorphisms 
and lack cardiovascular abnormalities, supporting a role for BAZ1B in neural crest-derived 
lineages; iii) two patients carrying the typical duplication of the 7q11.23 interval associated to 
language impairment, autism spectrum disorder and craniofacial dysmorphisms; and iv) two 
unaffected relative of a typical WBS patient, chosen as genetically half-matched control. All 
patients were already diagnosed at the molecular level by a combination of FISH, MLPA, and 
qPCR (as also shown in Fig.3.4B for the 7q11.23 aCGH profiles of representative case of each 
genotype).  
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Tab. 3.1 Clinical features of patients recriute in this study. NA, data not available. 
“+” stands for present; “-“ stands for not present. * bilateral cryptorchidism, penile 
hypospadia 
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4.2. Establishment of lentiviral-based somatic cell reprogramming 
First I established human somatic cell reprogramming using excisable polycistronic 
lentiviral vector (STEMCCA) in order to generate patient derived iPS cells (Fig. 3.1 A). This 
technology enables the excision of the viral transgenes in the reprogrammed clones by 
administration of Cre recombinase as the viral cassette is flanked by loxP sites. This could be 
important as the residual presence of the virus transgenes could generate unexpected long-
term instability and tumorigenicity due to permanent genetic integration (Pasi, Dereli-Oz et al. 
2011). Next, I characterized six independent clones using different in-vitro and in-vivo 
pluripotency assays (Fig. 3.1). Fig. 3.1 shows data from two representative iPSC lines from 
sample WBS2, in which I confirmed typical iPSC morphology (Fig. 3.1 B) and the expression 
of key pluripotency markers like NANOG, SSEA-3 and TRA-1-80 and alkaline phosphatase 
(Fig.3.1 C). Lentiviral induced PSC could from teratoma containing all three germ layers 
when they were injected into the flank of immmunodeficient mouse (Fig 3.1 E) Karyotyping 
analysis also has shown a stable cell line with a normal female karyotype (Fig. 3.1 F). 
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Fig. 3.1 Establishment and charactrization of lentiviral-based iPSC  
A) Scheme showing the protocol used for the generation of iPSC using excisable polycistronic 
lentiviral vector.  B) Morphology of established iPS lines by phase contrast microscopy. C) 
Expression of alkaline phosphatase by immunohistochemistry. D) Immunofluorescence 
detection of iPSC colonies expressing pluripotent markers NANOG (green), SSEA-3 (red) and 
Tra-1-80 (gray). Nuclei were stained with DAPI (blue). E) Teratomas containing all three 
germ layers were formed after subcutaneous injection of iPS cells into NOD-SCID mouse. F) 
Normal karotype of the patient derived iPSC clone. 
4.3. Differentiation of the iPSC toward cortical neurons through embryoid body 
intermediates 
I  then subjected six iPSC lines into cortical neural differentiation, by modifying a 
previously published protocol that taking advantage of several steps including of embryoid 
body and neural tube-like rosettes structures that can be subsequently split in order to establish 
neural progenitor cell (NPC) cultures (Brennand, Simone et al. 2011). The modifications are 
detailed in Fig. 3.2 A. I obtained neural tube-like rosettes structures and NPC that express 
defining neural stem cell markers such as Nestin, Pax6 and Sox2 (Fig. 3.2B and C). Prior to 
proceed with the differentiation of NPC toward mature neurons; I tested whether the 
reprogramming transgene had been silenced, since sustained expression would have likely 
hampered terminal neuronal differentiation. To do this, I performed immunobloting for the 
Oct-4 in iPSC-derived NPC and iPSC and the results confirmed the efficient silencing of virus 
transgene upon neural differentiation (Fig. 3.2D). Importantly, this result showed that virus 
transgene excision is not required to ensure robust differentiation. Finally, I differentiated 
neural progenitor cell toward mature neurons for 70 days (Fig. 3.2E).  
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4.3.1.1.  
4.3.1.2.  
 
Fig. 3.2  Differentiation of the virus iPSC toward cortical neurons through embryoid body 
intermediates. 
A) A Scheme showing the protocol has been exploited for neural differentiation of iPSC 
toward cortical neurons. B) Phase-contrast images of different stages of neural differentiation: 
early neural rosette (left), late neural rosettes (middle) following manual picking and plating 
of the early rosettes, and  established cultures of neural progenitors (right). C) Immunostaining 
of early neural rosettes, late neural rosettes and established neural progenitors showing the 
expression of neural stem cell markers Nestin (red), Pax6 and Sox2 (green). Nuclei were 
stained with DAPI (blue). D) Western blot showing complete silencing of Oct4 protein, 
including no expression of transgene-encoded  Oct4, in 2 independent lines of iPSC-derived 
neural progenitors. Undifferentiated iPSC expressed Oct4 and were used as controls (right 
lane). Vinculin was used as loading control. E) Phase contrast images of the cortical neurons 
post 70 days (left), neurons are infected by lentivirus expressing GFP under the promotor of 
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Synapsin. GFP positive neuron revealing the presence of synapsin expression in the mature 
neurons  (middle), patient derived terminal neurons are positive for MAP2AB and βIII-tubulin 
(right).  
 
4.4. Establishment of a large cohort of transgene-free induced pluripotent stem cell lines 
from WBS and 7dupASD patients 
Although my results showed that virus transgene excision is not required to ensure 
robust differentiation of iPSC toward neural lineages, residual presence of the virus transgenes 
could still generate unexpected long-term instability and tumorigenicity due to permanent 
genetic integration(Pasi, Dereli-Oz et al. 2011), To tackle this problems, I successfully 
established the most innovative reprogramming technology that is based on the daily 
transfection of synthetic mRNAs encoding the five pluripotency factors OCT4 (also known as 
POU5F1), SOX2, KLF4, LIN28 and c-MYC (Warren, Manos et al. 2010) (Fig. 3.3A). Besides 
a higher efficiency in terms of number of reprogrammed colonies and kinetics, this 
integration-free approach avoids the residual permanence of reprogramming transgenes and its 
detrimental impact in terms of inter-clones heterogeneity, variability in differentiation 
proficiency, insertional mutagenesis and reprogramming factors-induced DNA damage. 
Epithelial mesenchymal transition during reprogramming was tracked by nuclear GFP mRNA 
expression included in the transfection cocktail (Fig. 3.3B). Two weeks post transfection, 
three iPSC colonies per line (26 lines in total) were selected and picked on the basis of their 
typical ES-like morphology and positive staining for Tra-1-60 live antibody (Fig. 3.3C).  
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4.4.1.2.  
4.4.1.3.  
 
 
 
 
Fig 3.3 Establishment of a large cohort of transgene-free induced pluripotent stem cell lines 
from WBS and 7dupASD patients.  
A) A scheme showing the various steps during mRNA based reprogramming. B) GFP tracking 
of mesenchymal-to-epithelial transition and C) Tra-1-60 live staining used to identify fully 
reprogrammed cells prior to picking.  
 
I then characterized 3 independent iPSC lines from each patient or unaffected relative, 
along with 2 independent iPSC lines from the unrelated control individual, and one additional 
iPSC line previously reprogrammed by a conditional lentiviral vector following Cre-mediated 
excision of the single copy integrant amounting to a total cohort of 27 independent iPSC lines 
(Fig. 3.4 A).  
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Fig.3.4 Scheme showing the summary of clinical information overlaid onto the configuration 
of 7q11.23 rearrangements in individuals recruited for this study. 
A) Schematic representation of the WBS genetic interval (upper panel) and of the cohort of 
recruited patients including the number of independent iPSC clones derived per patients and a 
diagram showing the repertoire of clinical symptoms and cognitive behavioural traits (lower 
panels). Each genetic condition and the type of genetic rearrangement are represented with 
specific colors: typical WBS deletion (red), atypical deletion (orange) and 7q11.23 
microduplications (blue). iPSC lines derived from healthy individual are also shown (green), 
as well as external controls added for differential expression analysis. B) Copy number of 
Array-CGH probes in the 7q11.23 region for a patient sample representative of each genetic 
condition. One representative control line is included. C) Schematic representation of the 
WBS genetic interval and boundaries of the CNVs detected by aCGH. 
 
77 
 
 
Ectoderm Mesoderm Endoderm
DESS100 CKOCT4 SSEA3
NANOGDAPI
C
T
L
OCT4 SSEA3
NANOGDAPI
ALP
Ectoderm Mesoderm Endoderm
DESS100 CK
DESS100 CK
Ectoderm Mesoderm Endoderm
OCT4 SSEA3
NANOGDAPI
ALP
ALP
W
B
S
7
d
u
p
A
S
D
Tra-1-60 live
Tra-1-60 live
Tra-1-60 live
H&E
H&E
H&E
A B
POU5F1 
SOX2
iPSC lines exhibited typical morphology, expressed the full range of pluripotency 
markers including ALP, OCT4 (POU5F1), NANOG, Tra-1-60, SOX2 and SSEA-4, (Fig 3.5 
A-B) and contributed to the three embryonic germ layers upon teratoma assay in vivo (Fig. 3.5 
A). 
Fig 3.5. Characterization of mRNA based reprogrammed lines in this study  
A) Expression of ALP by immunohistochemistry. Immunostaining for pluripotency markers 
(left). Nuclei were stained with DAPI (blue). Staining of three representative iPSC-derived 
teratomas showing expression of markers specific for the three germ layers (right). B) 
Nanostring mesurement of POU5F1 (also known as OCT4) and SOX2 expression in the panel 
derived iPSC lines. Level of expression is indicated as normalized fields of view (FOV). 
 
4.5. Genomic instability of mRNA based reprogrammed iPSC 
During the recent years, there have been enormous efforts in understanding of the 
mechanisms underlying the genomic integrity in ESC and iPSC as it is vital for the future use 
of such pluripotent cells in disease modeling, regenerative medicine and drug screening fields. 
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For examples, alterations at the genomic level not only can lead to failure of transplanted cell 
function, but more importantly could potentially lead to tumorigenesis. Moreover, such 
changes at DNA lever may influence the cell's response to drugs, thus compromising the 
fidelity of drug screens and counter screens(Grskovic, Javaherian et al. 2011). 
In order to assess the genomic integrity of mRNA based reprogrammed iPSC lines, I 
isolated genomic DNA from at least 2 iPSC clones per individual along with their parental 
fibroblast and then we subjected them to high density CytoScan Arrays.  As shown in Table 2, 
very few copy number variants were identified in iPSC lines, most of which already pre-
existed in parental fibroblasts, consistent with recent evidence of pronounced CNV mosaicism 
in human skin from which ‘de novo’ iPSC-specific CNV emerge as a result of clonal 
expansion rather than genomic damage. 
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Tab. 3.2 Summary of the CNVs identified through aCGH. 
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4.6. Expression of 7q11.23 genes follows gene dosage in the pluripotent state 
In order to ascertain whether the pluripotent state represented a meaningful stage at 
which to probe the effect of 7q11.23 dosage, we first asked whether the mRNA expression of 
the 7q11.23 genes follows gene dosage. For this we resorted to the high accuracy of 
Nanostring-based quantification as well as to RNAseq and found that the expression of all 
genes of the interval (including those expressed at very low levels) mirrors gene dosage (Fig. 
3.6A), thus excluding compensatory effects from the wild type allele.  We then confirmed that 
also at the protein level the expression of both GTF2I and BAZ1B, the genes associated to key 
traits of WBS and 7DupASD(Hirota, Matsuoka et al. 2003, Edelmann, Prosnitz et al. 2007, 
Lazebnik, Tussie-Luna et al. 2009, Antonell, Del Campo et al. 2010, Sakurai, Dorr et al. 2011, 
Malenfant, Liu et al. 2012), reflected the symmetrical dosage of the two conditions (Fig. 3.6 
B-D). 
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Fig. 3.6 Expression of 7q11.23 genes follows gene dosage in the pluripotent state  
A) Nanostring quantification of the expression of genes included in the WBS genomic interval 
at the iPSC stage. Error bars represent the standard deviation in each genetic condition, while 
the horizontal bars above the respective comparisons indicate statistical significance. B) 
Western blot and (C-D) densitometry analysis of GTF2I and BAZ1B levels in a large portion 
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of WBS, 7dup-ASD and At-WBS samples compared to control (CTL). *: p < 0.05, **: p< 
0.01. 
 
4.7. 7q11.23 dosage imbalance causes transcriptional dysregulation in disease-relevant 
pathways already at the pluripotent state 
To assess differential expression between genotypes, we profiled by RNAseq the panel 
of patient- and control- derived iPSC lines, and complemented this dataset also with additional 
control lines from the literature (hereafter referred to as external controls, see methods), 
excluding from further analysis the genes that were differentially-expressed between controls 
from our cohort and external controls. A pair-wise comparison of the three genotypes 
identified 757 differentially-expressed genes (DEGs) (Fig. 3.7A). Strikingly, Gene Ontology 
(GO) analysis of the union of DEGs revealed significant enrichments for biological processes 
of obvious relevance for the hallmark phenotypes and target organ systems of the two 
conditions. Fig. 3.7 B shows a treemap representation of the most specific enriched biological 
processes (the full list of GO enrichments for each comparison are in shown is Fig. 3.7 C-F), 
in which square sizes are proportional to the significance of the enrichment The top-ranking 
categories are related on the one hand to cell adhesion, migration and motility, which appear 
especially relevant in light of the wide range of connective tissue alterations that characterize 
WBS, and to the nervous system, providing a molecular context for the defining 
neurodevelopmental features of the two conditions. In addition, further enrichments relate to 
remarkably specific features of the two diseases which include: i) cellular calcium ion 
homeostasis, a category of potential relevance across disease areas but that acquires particular 
salience in light of the high prevalence of hypercalcemia in WBS(Kruse, Pankau et al. 1992); 
ii) inner ear morphogenesis, consistent with the combination of hyperacusis and sensorineural 
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hearing loss that is virtually always present in WBS(Gothelf, Farber et al. 2006), as well as 
with the balance and sensory processing disorders found in ASD(Kern, Trivedi et al. 2006); 
iii) a number of categories relevant for the craniofacial phenotype, such as skeletal muscle 
organ development, migration and neural crest cell differentiation; and iv) categories such as 
blood vessel development and cardiovascular system development, that reflect the wide range 
of cardiovascular problems in WBS; v) kidney epithelium development, in line with the highly 
prevalent kidney abnormalities of WBS(Pankau, Partsch et al. 1996). Importantly, removal of 
the external controls did not lead to significant changes in the enrichments we obtained (Fig. 
3.7F), indicating that the cohort of our in-house reprogrammed lines already sufficed to 
capture the key features of 7q11.23-dependent transcriptional dysregulation. Furthermore, in 
order to exclude the possibility that such enrichments could arise by chance, we performed a 
series of shuffling tests entailing comparisons between randomly assigned groups of samples 
(see methods). In the rare cases in which these tests yielded any differentially expressed genes, 
the only significant GO enrichments arising within their union were related to extracellular 
matrix organization and response to mechanical stimulus. This points to these genes as 
particularly variable across lines and/or individuals, suggesting that enrichments related to 
these particular categories should be generally interpreted with care and underscoring the 
importance of subjecting GO enrichments to this rigorous scrutiny. Our analysis thus confirms 
that with the exception of these categories, the enrichments we found are specifically caused 
by 7q11.23 dosage imbalances. 
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Fig. 3.7 Analysis of the transcriptomic changes caused by 7q11.13 CNVs. 
A) Number and distribution of differentially-expressed genes (DEGs) among the three 
comparisons. B) Top most-specific enrichments for GO biological processes among DEGs. 
Parent categories with enriched children categories were filtered out; the color code indicates 
parent categories that have been selected approximating the best non-overlapping combination 
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of parents. DEGs show enrichment for categories recapitulating all aspects of the diseases. C-
E) GO biological processes enriched among DEGs between Control vs 7dupASD, WBS vs 
Control and WBS vs 7dupASD. F) Enrichment for GO biological processes among the union 
of DEGs when excluding the external control lines from the analysis. G) Principal component 
analysis of the published data comparing iPSC, IVF-derived hESC and SCNT-ESC
16
. Plotted 
are the first components able to distinguish, in the published data (after trimmed mean of M-
values normalization with ours), between iPSC and SCNT. Although our lines span the 
spectrum of variation on these components, most of them side with SCNT-ESc and IVF-ESc.  
 
We found that the majority of DEGs either show a symmetrically opposite pattern in 
the two conditions or have a fold-change in the same direction over controls, indicating that 
the symmetrical dosage imbalance affect mostly the same transcriptional programs, either in 
the same or in symmetrically opposite ways. We thus proceeded to uncover what were the 
most highly symmetrical genes, taking the DEGs for which the mean expression in control 
samples was within a 20-80% range between the means of the WBS and 7DupASD (~39% of 
the DEGs) and that had an absolute Pearson correlation of at least 0.5 with WBS gene dosage.  
This high-confidence set included 166 symmetrical DEGs (Fig. 3.8) (enriched for the 
single GO category of synaptic transmission), establishing that, in the pluripotent state, the 
symmetry in dosage is reflected into at least 22% of transcriptional dysregulation. Notably, 
this set includes genes associated to characterizing phenotypes of the 2 conditions, as in the 
case of PDLIM1 and MYH14, the former associated to attention-deficit disorder(Wang, Liu et 
al. 2012), neurite outgrowth(Ohno, Kato et al. 2009), cardiovascular defects, and hyperacusis, 
and the latter involved in hearing impairment and lip development(Martinelli, Arlotti et al. 
2008). 
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4.8. Transcriptional dysregulation in disease relevant cell 
types 
That 7q11.23 CNVs trigger disease-relevant 
transcriptional dysregulation already at the pluripotent state 
suggests that these initial conditions may prime the 
accumulation of even greater trascriptional alterations during 
development. Further, it predicts that the aggregate 
dysregulation in iPSC across categories spanning several 
developmental pathways and organ systems will be channeled 
upon differentiation, resulting in the selective amplification of 
specific domains of iPSC-specific dysregulation in a lineage-
dependent fashion.  
In order to test this hypothesis, we differentiated our 
iPSC lines into three lineages of cardinal relevance for the two 
conditions (Fig.  3.9): i) Pax6+ telencephalic neural stem cells 
and progenitors (NPC)(Shi, Kirwan et al. 2012, Shi, Kirwan et 
al. 2012); ii) neural crest stem cells (NCSC)(Menendez, Kulik 
et al. 2013), which originate the craniofacial structures along 
with several other disease-relevant lineages; iii) mesenchymal 
stem cells (MSC)(Menendez, Kulik et al. 2013), hierarchically 
upstream of osteocytes, chondrocytes, smooth muscle cells, 
and other physiopathologically meaningful cell types. 
 
Fig. 3.8 Genes 
differentially expressed in 
a symmetrical manner in 
WBS and 7dupASD iPSC. 
2.1.1.1.  
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Fig. 3.9 Scheme of iPSCs differentiation protocols toward cortical neurons (above) or 
osteocytes (below). 
 
4.9. Differentiation of iPSC toward cortical neuron using small molecules  
I successfully implemented the differentiation of iPSC into the dorsal telencephalic 
lineage by dual Smad inhibition in the presence of SB431542 and Noggin (Chambers, Fasano 
et al. 2009, Shi, Kirwan et al. 2012) (Fig. 3.10A). This protocol not only allows differentiation 
iPSC toward primary neuroepithelial cells but also captures in-vitro the three main progenitor 
populations of the human developing cortex (ventricular radial glia, intermediate progenitors 
and basal radial glia) which in turn generate the full range of early-born deep-layer and late-
born upper-layer cortical neurons, thereby allowing the in vitro recapitulation of human 
corticogenesis (Shi, Kirwan et al. 2012, Shi, Kirwan et al. 2012) .  I confirmed that patient-
derived NPCs expressed key forebrain markers such as FOXG1 (telencephalic marker), OTX2 
(forebrain marker)  and ZO1 (a marker for tight junctions, expressed in the lumen of neural 
iPSC
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B
rosettes), and were typically arranged in neural rosettes with TBR2+ intermediate progenitors 
surrounding apical Pax6+ progenitors (Fig.3.10B). Next, I directed the differentiation of 
neural progenitor cells toward terminally differentiated neurons by withdrawal of FGF. 
Cortical neurons then stained for the panel of lower and upper layers markers (Fig.3.10C) 
showing that this protocol is able to recapitulate key event of corticogenesis in-vitro. I profiled 
15 patient and control-derived NPC lines and found that most of the differentially expressed 
genes were enriched in GO categories related to neuronal function such as axon guidance, 
regulation of transmitter secretion and negative regulation of axonogenesis (Fig. 3.10D). 
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Fig. 3.10 Differentiation of iPSC toward cortical neuron using small molecules.   
A) Scheme of Differentiation of iPSCs to cortical neurons through stem/progenitor cells. 
Generation of cortical glutamatergic neurons from human iPSCs in vitro recapitulates in vivo 
corticogenesis.  B) iPSC-derived cortical stem/progenitor cells recapitulate the emergence of 
stem cell populations in human corticogenesis. Rosettes were stained for proliferating (Ki67), 
mitotic (phospho-histone H3) and neural stem cell (NESTIN, ZO1, and PAX6) markers 
(above). Default forebrain specification is evidenced by the expression of OTX2, FOXG1 and 
SOX2 markers (below). C) Images of human iPSC-derived cortical neurons expressing 
neuronal marker Tuj1. Deep and upper layer neurons were generated in the expected temporal 
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order, with layer 5 and 6 neurons (TBR1+, CTIP2+ and FOXP1+) emerging before layer 2/3 
neurons (BRN2+). Upper layer, later born cortical neurons, defined by the expression of 
CUX1, SATB2 and BRN2 transcription factors, emerge in this system several weeks after the 
early born, deep layer neurons. The overwhelming majority of neurons eventually acquire 
glutamatergic fate, as shown by the widespread appearance of vGlut1 and vGlut2 punctae on 
neurites. D) Top enrichments for GO biological processes among NPC DEGs. 
 
4.10.  Differentiation of iPSC to neural crest stem cells 
Craniofacial dysmorphic features are considered as one of the key hallmarks of WBS 
while they have also reported in 7dup-ASD patients (Merla et al., 2010; Pober, 2010; 
Somerville et al., 2005). This could point to the fact that aberrant expression of some residing 
genes in WBSCR may affect the common pathways involved in craniofacial phenotype. To 
test this hypothesis, I differentiated the same cohort of iPSC lines into NCSC that displayed 
distinct morphology (Fig. 3.11A), and stained homogeneously positively for HNK1 and 
NGFR, a defining combination of NCSC markers, in immunofluorescence (Fig. 3.11B), by 
flow cytometry (Fig. 3.11C) and qPCR (Fig.3.11D). Transcriptional profiling revealed 
differential expression in 364 genes (GO enrichments shown in Fig. 3.11E), including key 
genes linked to craniofacial dysmorphisms (ATP2C1, HHAT, LMNB1, MAPK8, PTCH1 and 
SATB2)(Dobreva, Chahrour et al. 2006, Singh, Yin et al. 2007, Cobourne, Xavier et al. 2009, 
Bonilla-Claudio, Wang et al. 2012, Dennis, Kurosaka et al. 2012, Metzis, Courtney et al. 
2013, Kurosaka, Iulianella et al. 2014, Zhao, Qu et al. 2014) and RhoA Signalling/Signalling 
by Rho Family GTPases (WASF1, GFAP, ACTR2, STMN1, MAPK8, ARHGEF11 and 
PLXNA1)(Minoux and Rijli 2010, Phillips, Papoutsi et al. 2012). Importantly, small GTPase 
RhoA signalling has been recently showed to rescue SM-actin filament bundle formation of 
smooth muscle cells in a model of WBS(Ge, Ren et al. 2012). 
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Fig. 3.11 Characterization of NCSC lines derived from WBS, atWBS, 7DupASD and control 
iPSC lines.  
A) Phase contrast microscopy shows a similar morphology between the four genotypes. B) 
Immunofluorescence analysis indicates positivity for two NCSC markers (HNK1 and NGFR) 
in a representative iPSC-derived NCSC line. C) Flow cytometry analysis indicates a high 
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percentage of HNK1-NGFR double positive cells in NCSC. D) RT-qPCR showing the 
expression of key neural crest markers. E) Top enrichments for GO biological processes 
among NCSC DEGs. 
4.11. Differentiation of iPSC toward mesenchymal stem cells 
Finally, in order to define the impact of iPSC-primed transcriptional deregulation upon 
further differentiation, I induced patient-derived NCSC towards the MSC fate in the presence 
of fetal bovine serum (FBS). Already four days after induction, all cells gained a MSC-like 
morphology (Fig. 3.12A) and positively stained for key mesenchymal stem cell markers CD44 
and CD73 (<95%) (Fig. 3.12B).  
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Fig. 3.12 Characterization of MSC lines derived from WBS, atWBS, 7DupASD and control 
iPSC lines.  
A) Phase contrast microscopy shows a similar morphology between the four genotypes. B) 
Flow cytometry analysis of MSCs for CD73+ and CD44+ cells at day 10 of differentiation.  
 
Transcriptomic profiling confirmed that, with the notable exception of ELN, also in 
MSC expression of 7q11.23 genes recapitulated dosage (Fig. 3.13 A-B), and yielded 422 
DEGs showing enrichment for several GO categories related to tissue morphology (Fig. 
3.13C).  Interestingly, and in contrast to iPSC, NPC and NCSC, shuffling tests (see methods) 
yielded enrichments in many of these same categories, though most often with much lower 
enrichment and significance. This may be due to the discrete statistics used for the analysis of 
RNAseq (vis a vis microarray data), which might amplify the effect of variability across 
samples. Alternatively, it may suggest that the MSC state is less homogeneous than the 
pluripotent state, manifesting itself as a less narrow attractor that is hence more sensitive to 
inter-individual divergence in gene expression. Regardless, removal of these potentially 
spurious genes from the DEGs led to the identification of the same major categories enriched 
among DEGs, indicating that their significance does not hinge on these variable genes. In 
addition, some categories of great interest for the craniofacial phenotypes, such as apoptotic 
processes or skeletal muscle tissue development, were wholly undetected in the shuffling 
analysis. These findings confirm that, even against the backdrop of significant inter-individual 
variability in gene expression, 7q11.23 dosage significantly affects disease-relevant pathways. 
In fact, and even more remarkably, samples clustered by genotype at the whole transcriptome 
level (Fig. 3.13D), indicating that 7q11.23 dosage imbalances have an especially high 
penetrance at this developmental stage. Strikingly, the atypical sample (AtWBS1-C2) 
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clustered with the controls, suggesting that spared genes are particularly important in this 
lineage, in line with recent reports of the role of BAZ1B in neural crest migration(Barnett, 
Yazgan et al. 2012). Moreover, an Ingenuity Pathway Analysis (IPA) on DEGs between WBS 
and CTL revealed a molecular network (the highest ranking network) enriched for genes 
related to cardiovascular system development (Fig. 3.13E) and including key regulators of 
cardiovascular development (Fig. 3.13F).  
 
 
Fig. 3.13 Transcriptomic profile of MSC lines derived from WBS, atWBS, 7DupASD and 
control iPSC lines.  
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A) Plot of RNAseq expression levels of genes included in the WBS genomic interval at the 
MSCs stage. For better visualization, genes were separated into low/medium (right panel) and 
high expression (left panel). B) RT-qPCR showing the expression of key ELN among various 
genotypes. C) Unsupervised hierarchical clustering of correlations between MSCs whole 
transcriptomes, showing that samples cluster according to their genotype. D) Top most 
specific enrichments for biological processes among the MSC DEGs.  E)  Ingenuity Pathway 
Analysis on MSC DEGs reveals a molecular network enriched for cardiovascular system 
development. E) Expression of key members of the network in MSC. Error bars represent the 
standard deviation, while the horizontal bars represent statistical significance. 
 
4.12.  Statistically significant overlap of DEG between iPSC and disease relevant cell 
types 
Given the physiopathological significance of the transcriptional dysregulation in MSC, 
we next asked what proportion of MSC-specific DEGs were also impacted at the iPSC state. 
As shown in Fig. 3.14A, 18% of MSC DEGs were already differentially-expressed in iPSC 
(25% when excluding external control iPSC), and the overlap steadily increases as we 
considered MSC DEGs with a higher expression in MSC, with 45% of the MSC DEGs 
expressed above 50 FPKM being found affected also in iPSC (Fig. 3.14B). Interestingly 
however, the proportion of overlapping DEGs did not correlate with expression at the iPSC 
stage (Fig. 3.14C), arguing against the hypothesis of greater accuracy at higher expression 
levels. We therefore hypothesized that genes that are dysregulated both in iPSC and MSC 
would be preferentially those that are specifically activated upon differentiation to MSC. 
Indeed, we found that of the iPSC DEGs that are down regulated upon differentiation to MSC 
(over 60%), very few remain differentially expressed also in MSC (Fig. 3.14D). In contrast, as 
we consider iPSC DEGs that increase expression upon differentiation to MSC, the proportion 
of DEGs maintained also in MSC rises to nearly 30%.  
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4.12.1.1.  
Fig. 3.14 Comparison of DEGs among various lineages.  
A) Overlap of DEGs identified in each lineage. Characterization of DEGs found in both iPSC 
and MSC. B) MSC DEGs that are also DEGs in iPSC have higher expression. C) The 
proportion of overlapping DEGs in MSCs does not correlate with expression levels in iPSC. 
D) The vast majority of DEGs at the iPSC stage is downregulated in differentiated MSCs and 
the overlap between iPSC and MSC DEGs increases with higher fold changes from iPSC to 
MSC.  
4.13. IPSC-specific transcriptional dysregulation is amplified during development in a 
lineage-specific manner  
On the basis of this analysis, we next hypothesized that the subset of iPSC DEGs that 
is conserved upon differentiation in each given lineage should be preferentially enriched in 
lineage-relevant categories. We thus evaluated, for each of the three differentiated lineages 
under study, the proportion of DEGs conserved for the GO categories that had been found 
enriched already in iPSC. As shown in Fig. 3.15 A-C and schematically represented in Fig. 
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4.1, upon differentiation iPSC DEGs are preferentially retained by category in a lineage-
appropriate manner so that, for each target lineage, the proportion of conserved iPSC DEGs is 
much greater in categories relevant to that lineage (such as axonogenesis and axon guidance in 
the neural lineage, synapse-related categories in NCSC that will originate the peripheral 
nervous system and smooth muscle related 
categories in MSC). 
Fig. 3.15 Lineage-specific retention of 
iPSC DEGs.  
(A-C) For each differentiated lineage, the 
treemap of enrichments that had been 
found among iPSC DEGs (Fig. 3.7B) is 
reproduced, plotting as a heatmap the 
proportion of iPSC DEGs in each category 
retained through differentiation.  
 
 
Finally, we noted that the proportion 
of symmetrically dysregulated genes is 
significantly higher among the DEGs that 
are in common between iPSC and 
differentiated lineages (average odd ratio 
~1.75, p~5e-03 evaluated from lineage-
specific Chi-squared tests compounded through Fisher's method), supporting the notion that 
symmetrical patterns, likely under more direct control by 7q11.23 dosage, are particularly 
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relevant for the quota of disease-relevant transcriptional dysregulation that is seeded already in 
the pluripotent state.  
4.14.  A web platform for 7q11.23 CNV syndromes 
Finally, the data I presented here were assembled by designing a new web platform 
called WikiWilliams-7q11GeneBase to make our data accessible to the community of 
scientists and practitioners working on these two diseases, through a user-friendly, gene-
centered interface. Besides integrating, in a multi-layered manner, all our results with data 
from the literature, WikiWilliams is open to contributions by other groups through submission 
to the database's curators, with the aim of assembling in one site all molecular data on 7q11.23 
syndromes (Fig. 3.16). The platform is openly accessible at http://bio.ieo.eu/wbs/. 
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Fig. 3.16 The WikiWilliams/7q11GB web platform.  
A)Schematic representation of the data gathered in the open-access WikiWilliams/7qGBb web 
platform. B-D)Representative screenshot of the WikiWilliams/7q11GB database as it appears 
to users searching for a specific gene of interest. All transcriptomic and genomic data 
presented in this paper as well as previously published datasets can be easily interrogated in a 
multi-layered format integrated with several biological databases. 
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5. Discussion 
In spite of increasing amount of information and huge investments by the 
pharmaceutical industry on genetic and age-associated disorders, the development of novel 
therapeutics in particular for cardiovascular abnormalities and neurological disorders has 
proven to be challenging and thus few new therapeutic compounds are presently entering the 
market. This is partially owing to experimental tools including in vitro cultures and animal 
models which can recapitulate only some of the specific traits of human disease and thus 
makes the modeling of human diseases in laboratory very difficult (Bellin, Marchetto et al. 
2012). 
The generation of induced pluripotent stem cells (iPSC) from terminally differentiated 
cells holds great promise for disease modeling, drug discovery and regenerative medicine 
(Ming et al., 2011). Ectopic expression of defined pluripotency factors generates patient-
specific pluripotent cells that can be then differentiated into relevant cell types to gain 
mechanistic insights into disease physiopathology. This technology is enabling researchers to 
undertake studies for functional annotation of human genomes and modeling diseases ‘in a 
dish’, which was previously inconceivable, promising to align well defined genetic lesions to 
clinical data through molecular phenotypes in vitro (Bellin, Marchetto et al. 2012).   
To this end, the critical challenge is twofold: i) define the extent to which early 
developmental lineages are informative about disease-relevant pathways affected by genetic 
mutations and, ii) assess the feasibility of reliably identifying those pathways beyond the 
sources of variability inherent to the iPSC-based approach (Cahan and Daley 2013). 
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Here I addressed these questions by focusing on a paradigmatic pair of genetic 
syndromes caused by symmetrical copy number variations (CNV) at 7q11.23: Williams-
Beuren syndrome and Williams-Beuren region duplication syndrome that includes autistic 
spectrum disorder (7dupASD) (Sanders, Ercan-Sencicek et al. 2011). WBS and 7dupASD 
involve, respectively, the loss or gain of 26-28 genes and have a prevalence of between 1 in 
7,500 and 1 in 10,000 (Somerville, Mervis et al. 2005, Pober 2010). WBS is characterized by 
cardiovascular symptoms and facial dysmorphism, along with the hallmark behavioral-
cognitive profile that combines hypersociability with comparatively well-preserved language 
abilities, but severely compromised visuo-spatial processing, counting and planning (Merla, 
Brunetti-Pierri et al. 2010, Pober 2010). 7dupASD, in contrast, features varying degrees of 
ASD ranging from severe speech impairment to full blown autism, along with craniofacial 
dysmorphisms, among which some are similar and some symmetrically opposite to those of 
WBS patients (Somerville, Mervis et al. 2005, Van der Aa, Rooms et al. 2009). Finally, both 
syndromes are associated with anxiety and attention deficit hyperactivity disorder (ADHD). 
Thus, the two conditions are paradigmatic of a fundamental aspect of CNV-based disease 
pairs, namely the fact that symmetrically opposite CNV result in shared as well as 
symmetrical phenotypes. Yet, despite significant insight from mouse models (Osborne 2010, 
O'Leary and Osborne 2011, Campuzano, Segura-Puimedon et al. 2012, Mervis, Dida et al. 
2012), the molecular pathways specifically affected by 7q11.23 CNV in the human lineages 
that are most relevant for disease phenotypes are yet to be uncovered. 
Here we present the largest cohort of WBS and 7dupASD iPSC lines and differentiated 
lineages, in which we find that 7q11.23 dosage impacts disease-relevant transcriptional 
programs already in the pluripotent state. These alterations are partitioned into shared and 
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symmetrically opposite ones and are further exacerbated upon differentiation into disease-
relevant lineages.  
Somatic cell reprogramming is limited by: i) low efficiency of iPSC derivation; ii) the 
risk of insertional mutagenesis and iii) residual transgene expression from integrated vectors 
(Anokye-Danso et al., 2011; Pasi et al., 2011b; Takahashi et al., 2007).  To tackle these issues, 
many non-integrating platforms have been developed which allows reprogramming of human 
somatic cells to iPSC using modified mRNA or specific clusters of miRNA (Warren, Manos et 
al. 2010, Anokye-Danso, Trivedi et al. 2012). Here for the first time, I unveil the 
combinatorial potential of the reprogramming approach through the generation and full 
characterization of iPSC from a large cohort of patients affected by WBS and 7Dup-ASD 
based on miRNA enhanced-mRNA method in feeder-free conditions. I validated the 
pluripotency of these cells on the basis of expression of well-recognized pluripotency markers, 
maintenance of undifferentiated morphology upon several passages in feeder-free conditions 
and tri-lineage and lineage-directed differentiation in-vitro and in-vivo. Moreover, genomic 
integrity of iPSC lines were assessed at high resolution, finding only few CNV, the 
overwhelming majority of which pre-existed in parental cells, consistent with recent studies 
showing CNV mosaicism within parental cells prior to reprogramming (Abyzov et al., 2012). 
These results showed that the combination of miRNA and mRNA based approaches through a 
novel RNA delivery technology, besides preventing insertional mutagenesis and the persistent 
expression of reprogramming factors inherent to viral-based technologies, offers 
unprecedented efficiency. Furthermore, the addition of miRNAs to the previously described 
mRNA cocktail (OCT4, SOX2, KLF4, c-MYC, LIN28) further shortens the process to less 
than two weeks, reducing the time needed to obtain clinically relevant integration-free human 
iPSC and without detectable accumulation of reprogramming-induced mutations. 
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The unique size of this cohort, both in terms of number of individuals and of 
independent iPSC clones derived from each individual, allowed us to address two main 
questions I have mentioned above; first, to define the extent to which early developmental 
lineages are informative about disease-relevant pathways affected by 7q11.23 dosage 
imbalances, we looked at the expression of the WBS genes using high accuracy Nanostring-
based quantification. The results showed that the expression of all WEB genes follows gene 
dosage. Next, the impact of such 7q11.23 dosage imbalances was probed by high throughput 
RNA sequencing. We found that 7q11.23 causes profound transcriptional dysregulation 
already in the pluripotent state, strikingly affecting major disease-relevant pathways. Although 
recently published gene expression profiling experiment in non-relevant cells types such as 
lymphoblasts have revealed abnormal regulation of gene pathways potentially related to 
relevant aspects of the WBS syndrome phenotype, (Antonell et al., 2010b), this is the first 
time that high-throughput transcriptional profiling at very early stage of development i.e., 
iPSC could detect advanced phenotype of disease such as cellular calcium ion homeostasis, 
inner ear morphogenesis, craniofacial phenotype, blood vessel development and 
cardiovascular system development and kidney epithelium development. This implies that 
physiological development is biased already from early embryogenesis as a result of 7q11.23 
imbalances.   
These findings also allowed us to answer the second main question in the field which 
is the feasibility of reliably identifying indentified pathways beyond the sources of variability 
inherent to the iPSC-based approach. As extensively discussed in the introduction , variability 
has been recently recognized as a key concern for iPSC-based disease modeling, inviting 
caution in the interpretation of results from few lines that do not adequately sample variability 
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either across individuals or across lines reprogrammed from the same individual (Cahan and 
Daley 2013).  
In order to exclude the possibility that such enrichments in disease relevant pathway 
could arise by chance or as a result of variability in iPSC lines, we performed a series of 
experiment. First, we excluded the fact that such enrichment could be due to the fewer number 
of the control lines with respect to the disease derived iPSC line by including additional 
control from the literature. In order to minimize the potential bias produced by including 
external samples for only one of the conditions, we chose to add three samples (each coming 
from a different individual) -- that is, half the number of control lines we already had -- and 
excluded from further analysis any gene that was differentially-expressed between virus and 
mRNA-reprogrammed control lines. Although the vast majority of DEGs identified were 
already detected in the previous analysis, the introduction of new samples increased, as 
expected, variability among the controls and led to the loss of over a hundred DEGs (including 
some WBS genes whose differential expression we are very confident about based on 
independent Nanostring validation, thus highlighting inherent limitations in sensitivity when 
analyzing large cohorts of heterogeneous human samples by high throughput methods). 
Nevertheless, the main messages of the results remained entirely corroborated, and in fact 
some of the GO enrichments even increased in statistical significance. Importantly, the vast 
majority of differentially-expressed genes identified in this study were still found when 
removing the external controls, and most of the remaining DEGs were close to significance, 
arguing against the introduction of a major bias through the use of external controls. 
In order to assess the effect, on the transcriptional analysis, of having fewer samples, 
we repeated the analysis of our polyA dataset (focusing on the comparison for which we had 
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the most samples, i.e. the global analysis of WBS vs CTL iPSC), using only subsets of the 
samples. Random removal of 1 clone per patient lead to a dramatic reduction in the number of 
DEGs (48 to 76% lost), and to the identification of DEGs that are falsified by the discarded 
data. The impact of removing all clones from one patient per condition (amounting to fewer 
samples than removing one clone per patient) was even greater. In contrast, depth of 
sequencing appeared to make little difference: reducing coverage by half led to the loss of 
11% of DEGs and to very few false positives. 
Next, to assess the possibility that the observed differential expression might arise due 
to random variations, we performed a series of differential expression analysis between 
randomly-selected samples, discarding comparisons in which the two groups were not 
balanced for sex and/or genotype. A minimum of 3 such combinations were tested per tissue, 
and the resulting genes were pooled for the purpose of enrichment analysis. 
We first randomly assigned all patients to two groups, but we could obtain statistically 
significant genes in none of the combinations. We therefore gradually removed patients until 
significant genes were obtained, which did not happen until a comparison involving 6 vs 6 
samples (in each group, 3 samples from 2 patients). In contrast, when clones were selected and 
assigned to groups in a way that maximized the number of patients represented in each group, 
we had to go down to 3 vs 3 (3 samples per group, coming from 3 different patients) to get 
statistically significant genes (18 DEGs, showing no significant GO enrichment). Similarly, 
random allocation of the control samples (including external controls, balanced across groups) 
yielded very few DEGs (maximum 17) and no significant GO enrichment. 
These results suggest that the primary source of “spurious” differential expression is 
genetic variation between individuals, which only gets mitigated using lines derived from 
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several patients and thus confirms that with the exception of these categories, the enrichments 
we found are specifically caused by 7q11.23 dosage imbalances.  
And finally, we confirmed that our iPSC lines share the pluripotent signature of 
published datasets and hence GO enrichment in disease relevant pathways could not be due to 
the spontaneous differentiation potential of our iPSC lines in culture. Indeed, with respect to 
the recent comparison of traditionally reprogrammed iPSC versus embryonic stem cell lines 
derived by nuclear transfer (NT-ES) or in vitro fertilization (IVF-ES)(Ma, Morey et al. 2014) 
the majority of our lines (over 2/3) sided with NT-ES and IVF-ES with respect to the 
transcriptional components distinguishing published iPSC from NT-ES/IVF-ES 
(Supplementary Fig. 3a). 
Thus, by presenting the largest cohort of iPSC lines characterized so far for any single 
genetic condition, combined to the first large scale use of mRNA-based integration-free 
reprogramming, our study benchmarks the possibility of detecting robust dosage-dependent 
alterations in transcriptional programs, even when these are caused by subtle dosage 
imbalances.  
We further confirmed this finding by differentiating our cohort of iPSC lines into three 
lineages of cardinal relevance for the two conditions: dorsal telencephalic progenitors and 
neural crest stem cells along with their further differentiated mesenchymal derivatives, 
respectively relevant for the cognitive/behavioral and craniofacial phenotypes of WBS and 
7dupASD. We found not only that each differentiated cell type displayed specific 
transcriptional alterations that match the relevant disease domains, but also that these 
alterations were seeded to a significant extent already in iPSC and were in fact amplified, 
upon differentiation, in a lineage-specific manner. 
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The size and quality of our iPSC cohort not only permitted us to understand the impact 
of 7q11.23 CNV on transcriptional dysregulation in the pluripotent state; but more importantly  
allowed us to found out that this dysregulation was selectively amplified in a lineage-specific 
manner, with disease-relevant pathways preferentially and progressively more affected in 
differentiated lineages matching specific disease domains.  The significance of this 
observation for the iPSC modeling field lies in the fact that the pluripotent state is by far the 
best characterized and most standardized one among the human developmental stages 
captured in vitro. Importantly, it is also the most amenable to high-throughput upscaling. 
Hence, the observation that the pluripotent state is not only a viable stage in which to measure 
disease-relevant transcriptional effects of genetic alterations, but that these effects are also 
predictive of further dysregulation in differentiated lineages, grounds the feasibility of middle-
to-high-throughput iPSCs characterization in order to functionally annotate human genomes, 
prior to selecting lines and assays for more labor-intensive differentiation courses. 
In terms of the molecular pathogenesis of WBS and 7dupASD, besides uncovering the 
impact of 7q11.23 dosage already in the pluripotent state, these results also provide a first 
entry point for the molecular dissection of the outstanding feature that characterizes these two 
conditions, namely the coexistence, in the face of symmetrically opposite CNV, of both shared 
and symmetrically opposite phenotypes. By analyzing many samples from both conditions, we 
were in fact able to define a subset of DEGs that follows a symmetrically opposite dosage-
dependent trend. Importantly, we found that this quota is significantly retained upon 
differentiation, indicating that symmetrically opposite patterns of gene expression seeded 
already in the pluripotent state, likely under direct control of 7q11.23 dosage, become 
increasingly prominent in disease-relevant differentiated lineages, thus providing a strong 
rationale for studying these two diseases (and by implication other CNV-based symmetric 
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disease pairs) together. Importantly, our analysis of symmetrically dsyregulated targets also 
uncovered the following genes as prime candidates for mediating the molecular pathogenesis 
of defining aspects of the two conditions: i) PDLIM1, which has been associated to attention-
deficit disorder, neurite outgrowth, cardiovascular defects, and hyperacusis; ii) MYH14, 
which was involved in hearing impairment and lip development; iii) BEND4, a TF harboring 
the BEN domain that distinguishes a recently characterized family of neural repressors. 
Finally, the data I presented here were provided in a user-friendly, open source web 
platform in which we assembled the multi-layered datasets from this first cohort of WBS and 
7dupASD samples, and which was designed to integrate ongoing contributions from the entire 
scientific community working on these two diseases, thus serving also as a first template for 
data sharing from iPSC-based functional genome annotation.  
In conclusion, reprogramming the paradigmatic pair of genetic syndromes caused by 
symmetrical 7q11.23 CNV enabled us to define how gene dosage impacts disease-relevant 
pathways in early developmental lineages and disease relevent cell types. These findings have 
broad significance for the molecular pathogenesis of WBS and 7dupASD as well as for the 
reprogramming-based disease modeling field as a whole.  
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Fig.4.1 Graphical representation of the lineage specific retention of DEGs.  
6. Future direction 
 
6.1. A novel strategy for differentiation of iPSC toward homogenous population of 
cortical neural progenitors and neurons 
Understanding the molecular mechanism of disease through somatic cell 
reprogramming riles to a large extent on the robust and reliable differentiation methods which 
can faithfully produce patient derived disease-affected cell types as pathophysiologically 
relevant in vitro models. To this aim, numerous protocols has been developed which enable 
differentiation of PSC toward neural and non-neural differentiation (Chambers, Fasano et al. 
2009, Brennand, Simone et al. 2011, Shi, Kirwan et al. 2012, Menendez, Kulik et al. 2013) . 
Such a protocol should be able to produce step wise synchronized cells types in terms of 
differentiation which would allow us to understand the stages from which disease phenotype 
start to emerge and/or stages that mostly affected during differentiation process. Yet, 
development of a protocol which can synchronously produced NPC or cortical neuron is not 
fully addressed. To this goal and based on such considerations, I have designed and developed 
a protocol which can allow the selection of NPC cells which are positively expressing 
forebrain marker FOXG1. This protocol takes advantage of lentivrial vector in which 
puromycin resistance gene is expressed under the control of FOXG1 promoter and eGFP 
under control Of CMV promoter (Fig. 5.1A). Briefly, virus particles were produced using 
third generation packaging system in HEK 293 cells (Fig. 5.1B) and then iPSC cells were 
infected with the various concentrations of the virus and two day post infection FACS analysis 
performed to find the concentration of the virus which can maximize the infection efficiency 
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(Fig. 5.1 C-D). The infected iPSC which expressed GFP will be differentiated by the blockade 
of Smad signaling pathway (please see the materials and methods) and at the NPC stage, cells 
will be supplemented with puromycine to undergo selection. FOXG1 expressing cells will be 
assessed by immunostaing to ensure the identity of the selected NPC and prior to further 
differentiation. Finally NPC and differentiated cells will be compared with same cell line 
which has not undergone the selection steps and the results will be assessed by various 
technique including immunostaining and RNA-Seq.  
 
 
 
 
 
 
 
 
 
Fig. 5.1 A novel strategy for differentiation of iPSC toward homogenous population of cortical 
neural progenitors.  
A) Scheme of the lentiviral vector with eGFP under control Of  CMV promoter and 
puromycin under  control of human FOXG1B promoter. B) HEK 293 cells expressed GFP one 
day post transfection. C) Optimizing viral infection to maximize the infection efficiency prior 
to differentiation. iPSC were infected with various concentration of the virus. D) FACS results 
showed the number of the infected cells in each condition.  
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6.2. Differentiation of homogenous population of MSC toward disease affected cell types 
The second key question that I would like to address is to find a differentiation stage 
throughout MSC differentiation protocol in which various patients and healthy individual 
derived cell type are highly homogenous and thus they can be subjected for the further cellular 
or molecular characterization to probe the disease phenotype. My results showed that not all 
iPSC cells could give rise to homogenous population of the NCSC based on the expression of 
the two key NCSC markers, HNK1 and NGFR shown by FACS analysis (Fig.3.12 ). For this 
reason only, iPSC derived NSCS line which highly expressed these markers were selected for 
further differentiation toward MSC (Fig.3.11 and Fig.3.12 ). The unsupervised clustering 
analysis based on the global genes expression profiling showed that MSC but not NCSC were 
segregated based on their biological condition suggesting that MSC differentiation protocol is 
able to robustly differentiate NCSC toward highly homogeneous population of MSC. To 
further test this hypothesis, I perform another round of differentiation in which I subjected not 
fully differentiated NSCS lines along with not fully differentiated ones to MSC differentiation 
assay and asked if the differentiation media can favor the survival and maintenance of fully 
differentiated MSC.   Strikingly, the FACS analysis showed that even from not HNK1 and 
NGFR double positive NCSC we can obtain a homogeneous population of the MSC which 
can express MSC key markers (Fig.5.2 A-B).  In order to understand if the newly generated 
MSC lines will be clustered with their relevant genotype we will perform RNA-seq on these 
lines.  Finally MSC will be further differentiated toward cell types which are affected in the 
patient such as smooth muscle cells and osteblasts in order to probe the disease phenotype in 
more advance stages of the disease.  
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Fig. 5.2 Differentiation of NSCS toward MSC. 
A) FACS analysis for iPCS derived NCSC lines showed that not all iPSC can efficeintly 
differentiate toward NCSC. B) FACS analysis for CD44 and CD73, two MSC key markers 
showed that even not fully differentiated NCSC can differentiate toward double positive MSC.   
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